

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request cder_mpl1r_wp242

Request ID: cder_mpl1r_wp242_nsdp_v01

<u>Request Description:</u> In this report we characterized dispensing and administration patterns of 15 New Molecular Entities (NMEs) approved from September 1, 2020 to December 31, 2020, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.0.0

<u>Data Source</u>: We distributed this request to 12 Sentinel Data Partners (DP) on May 11, 2023. The study period included data from January 1, 2020 to most recent available data. Please see Appendix A for a list of dates of available data for each Data Partner.

<u>Study Design:</u> We identified individuals initiating any of the 15 NME drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

<u>Exposures of Interest</u>: Our exposures of interest were NMEs approved between September 1, 2020 to December 31, 2020, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

<u>Cohort Eligibility Criteria:</u> We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

cder_mpl1r_wp242 Page 1 of 302



Overview for Request cder_mpl1r_wp242

<u>Limitations:</u> Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

¹Chronic Conditions Data Warehouse. Condition Categories - Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories.

cder_mpl1r_wp242 Page 2 of 302



- **Glossary** List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report **(CIDA)**
- <u>Table 1a</u> Aggregated Characteristics of Ansuvimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1b</u> Aggregated Characteristics of Atoltivimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1c</u> Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1d</u> Aggregated Characteristics of Copper in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1e</u> Aggregated Characteristics of Gallium in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1f</u> Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1g</u> Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1h</u> Aggregated Characteristics of Margetuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1i</u> Aggregated Characteristics of Naxitamab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1j</u> Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1k</u> Aggregated Characteristics of Relugolix in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 11</u> Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1m</u> Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 1n</u> Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 10</u> Aggregated Characteristics of Vibegron in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 2a</u> Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 2b</u> Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 2c</u> Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 2d</u> Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 2e</u> Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 2f</u> Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 3a</u> Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 3b</u> Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

cder_mpl1r_wp242 Page 3 of 302



- <u>Table 3c</u> Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 3d</u> Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 3e</u> Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 3f</u> Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 4a</u> Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 4b</u> Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 4c</u> Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 4d</u> Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 4e</u> Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 4f</u> Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 5a</u> Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 5b</u> Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 5c</u> Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 5d</u> Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 5e</u> Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 5f</u> Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 6a</u> Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 6b</u> Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 6c</u> Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 6d</u> Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 6e</u> Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 6f</u> Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 7a</u> Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 7b</u> Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

cder_mpl1r_wp242 Page 4 of 302



- <u>Table 7c</u> Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 8a</u> Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 8b</u> Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex
- <u>Table 8c</u> Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group
- <u>Table 9</u> Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Table 10</u> Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1a Patient Entry into Study by Month for Ansuvimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1b Patient Entry into Study by Month for Atoltivimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Figure 1c</u> Patient Entry into Study by Month for Berotralstat in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1d Patient Entry into Study by Month for Copper in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1e Patient Entry into Study by Month for Gallium in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Figure 1f</u> Patient Entry into Study by Month for Lonafarnib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1g Patient Entry into Study by Month for Lumasiran in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1h Patient Entry into Study by Month for Margetuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Figure 1i</u> Patient Entry into Study by Month for Naxitamab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1j Patient Entry into Study by Month for Pralsetinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Figure 1k</u> Patient Entry into Study by Month for Relugolix in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- <u>Figure 11</u> Patient Entry into Study by Month for Remdesivir in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1m Patient Entry into Study by Month for Setmelanotide in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Figure 1n Patient Entry into Study by Month for Tirbanibulin in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- **Figure 10** Patient Entry into Study by Month for Vibegron in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022
- Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 11, 2023)
- Appendix B List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
- Appendix C List of Procedure Codes Used to Define Exposures in this Request

cder_mpl1r_wp242 Page 5 of 302



Appendix D
List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Appendix E List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix F Specifications Defining Parameters for this Request

Appendix G Parameters Used to Define Baseline Characteristics for this Request

Appendix H Design Diagram of Cohort Entry Requirements and Index Exposure for this Request

cder_mpl1r_wp242 Page 6 of 302



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

cder_mpl1r_wp242 Page 7 of 302



Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered. **Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

cder_mpl1r_wp242 Page 8 of 302



Table 1a. Aggregated Characteristics of Ansuvimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	0	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	-	
Age	Number	Percent
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ¹		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	-
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease and related conditions	-	-
Atrial Fibrillation	-	-
Diabetes mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-



Table 1a. Aggregated Characteristics of Ansuvimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related prescriptions	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related prescriptions	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-

Mean number of filled prescriptions Mean number of generics dispensed

Mean number of unique drug classes dispensed

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not Applicable



Table 1b. Aggregated Characteristics of Atoltivimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	0	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	-	-
Age	Number	Percent
0-17 years	-	-
18-24 years	-	-
25-40 years	-	-
41-64 years	-	-
≥ 65 years	-	-
Sex		
Female	-	-
Male	-	-
Race ¹		
American Indian or Alaska Native	-	-
Asian	-	-
Black or African American	-	-
Native Hawaiian or Other Pacific Islander	-	-
Unknown	-	-
White	-	-
Hispanic origin		
Yes	-	-
No	-	-
Unknown	-	-
Year		
2020	-	-
2021	-	-
2022	-	<u>-</u>
Health Characteristics		
Acute Myocardial Infarction	-	-
Alzheimer's Disease and related conditions	-	-
Atrial Fibrillation	-	-
Diabetes mellitus	-	-
Heart Failure	-	-
Hyperlipidemia	-	-
Hypertension	-	-
Depression	-	-
Ischemic Heart Disease	-	-



Table 1b. Aggregated Characteristics of Atoltivimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	-	-
Stroke/TIA	-	-
Breast Cancer	-	-
Colorectal Cancer	-	-
Prostate Cancer	-	-
Lung Cancer	-	-
Endometrial Cancer	-	-
Acquired Hypothyroidism	-	-
Anemia	-	-
Asthma	-	-
Benign Prostatic Hyperplasia	-	-
Chronic Kidney Disease	-	-
COPD and Bronchiectasis	-	-
Glaucoma	-	-
Osteoporosis	-	-
Obesity: diagnosed or identified by weight management procedures	-	-
Obesity: identified by weight management-related prescriptions	-	-
Overweight	-	-
Smoking: diagnosed or identified by smoking cessation procedures	-	-
Smoking: identified by smoking-related prescriptions	-	-
Alcohol Abuse or Dependence	-	-
Drug Abuse or Dependence	-	-
History of Cardiac Arrest	-	-
History of Coronary Angioplasty or Bypass	-	-
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	-	-
Mean number of emergency room encounters	-	-
Mean number of inpatient hospital encounters	-	-
Mean number of non-acute institutional encounters	-	-
Mean number of other ambulatory encounters	-	-
Mean number of filled prescriptions	-	-

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

N/A: Not Applicable

Mean number of generics dispensed

Mean number of unique drug classes dispensed



Table 1c. Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Jnique patients	191	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	51.5	15.3
Age	Number	Percent
0-17 years	****	****
18-24 years	****	****
25-40 years	33	17.3%
41-64 years	82	42.9%
≥ 65 years	55	28.8%
Sex .		
Female	142	74.3%
Male	49	25.7%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	12	6.3%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	89	46.6%
White	90	47.1%
Hispanic origin		
Yes	****	****
No	****	****
Unknown	99	51.8%
Year		
2020	****	****
2021	118	61.8%
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	****	****
Atrial Fibrillation	****	****
Diabetes mellitus	24	12.6%
Heart Failure	****	****
Hyperlipidemia	38	19.9%
Hypertension	57	29.8%
Depression	45	23.6%
Ischemic Heart Disease	20	10.5%



Table 1c. Aggregated Characteristics of Berotralstat in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	35	18.3%
Stroke/TIA	****	****
Breast Cancer	****	****
Colorectal Cancer	****	****
Prostate Cancer	****	****
Lung Cancer	0	0.0%
Endometrial Cancer	****	****
Acquired Hypothyroidism	27	14.1%
Anemia	34	17.8%
Asthma	26	13.6%
Benign Prostatic Hyperplasia	****	****
Chronic Kidney Disease	17	8.9%
COPD and Bronchiectasis	14	7.3%
Glaucoma	****	****
Osteoporosis	****	****
Obesity: diagnosed or identified by weight management procedures	39	20.4%
Obesity: identified by weight management-related prescriptions	****	****
Overweight	22	11.5%
Smoking: diagnosed or identified by smoking cessation procedures	29	15.2%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	****	****
Drug Abuse or Dependence	14	7.3%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	****	****

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	15.1	18.5
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.3	1.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.7	11.5
Mean number of filled prescriptions	19.8	19.6
Mean number of generics dispensed	7.5	6.1
Mean number of unique drug classes dispensed	7.0	5.5

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1d. Aggregated Characteristics of Copper in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	506	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	59.9	12.8
Age	Number	Percent
0-17 years	****	****
18-24 years	****	****
25-40 years	****	****
41-64 years	277	54.7%
≥ 65 years	183	36.2%
Sex		
Female	271	53.6%
Male	235	46.4%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	****	****
Black or African American	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	399	78.9%
White	88	17.4%
Hispanic origin		
Yes	****	****
No	0	0.0%
Unknown	****	****
Year		
2020	****	****
2021	****	****
2022	325	64.2%
Health Characteristics	<u></u>	<u> </u>
Acute Myocardial Infarction	****	****
Alzheimer's Disease and related conditions	****	****
Atrial Fibrillation	26	5.1%
Diabetes mellitus	117	23.1%
Heart Failure	30	5.9%
Hyperlipidemia	162	32.0%
Hypertension	227	44.9%
Depression	90	17.8%
Ischemic Heart Disease	79	15.6%



Table 1d. Aggregated Characteristics of Copper in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	66	13.0%
Stroke/TIA	****	****
Breast Cancer	16	3.2%
Colorectal Cancer	16	3.2%
Prostate Cancer	****	****
Lung Cancer	22	4.3%
Endometrial Cancer	****	****
Acquired Hypothyroidism	62	12.3%
Anemia	143	28.3%
Asthma	32	6.3%
Benign Prostatic Hyperplasia	18	3.6%
Chronic Kidney Disease	74	14.6%
COPD and Bronchiectasis	31	6.1%
Glaucoma	****	****
Osteoporosis	13	2.6%
Obesity: diagnosed or identified by weight management procedures	149	29.4%
Obesity: identified by weight management-related prescriptions	****	****
Overweight	58	11.5%
Smoking: diagnosed or identified by smoking cessation procedures	112	22.1%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	****	****
Drug Abuse or Dependence	16	3.2%
History of Cardiac Arrest	****	****
History of Coronary Angioplasty or Bypass	18	3.6%

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	16.6	12.2
Mean number of emergency room encounters	0.6	1.3
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.7	5.0
Mean number of filled prescriptions	15.8	15.7
Mean number of generics dispensed	7.0	5.4
Mean number of unique drug classes dispensed	6.6	5.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1e. Aggregated Characteristics of Gallium in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	1,879	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	73.9	6.8
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	152	8.1%
≥ 65 years	1,727	91.9%
Sex		
Female	****	****
Male	****	****
Race ¹		
American Indian or Alaska Native	****	****
Asian	****	****
Black or African American	81	4.3%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	536	28.5%
White	1,213	64.6%
Hispanic origin	,	
Yes	13	0.7%
No	1,291	68.7%
Unknown	575	30.6%
Year		
2020	****	****
2021	****	****
2022	1,082	57.6%
Health Characteristics		
Acute Myocardial Infarction	****	****
Alzheimer's Disease and related conditions	34	1.8%
Atrial Fibrillation	183	9.7%
Diabetes mellitus	273	14.5%
Heart Failure	111	5.9%
Hyperlipidemia	746	39.7%
Hypertension	821	43.7%
Depression	166	8.8%
Ischemic Heart Disease	411	21.9%



Table 1e. Aggregated Characteristics of Gallium in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	266	14.2%
Stroke/TIA	30	1.6%
Breast Cancer	186	9.9%
Colorectal Cancer	11	0.6%
Prostate Cancer	1,764	93.9%
Lung Cancer	****	****
Endometrial Cancer	****	****
Acquired Hypothyroidism	129	6.9%
Anemia	382	20.3%
Asthma	42	2.2%
Benign Prostatic Hyperplasia	242	12.9%
Chronic Kidney Disease	217	11.5%
COPD and Bronchiectasis	50	2.7%
Glaucoma	95	5.1%
Osteoporosis	67	3.6%
Obesity: diagnosed or identified by weight management procedures	191	10.2%
Obesity: identified by weight management-related prescriptions	****	****
Overweight	130	6.9%
Smoking: diagnosed or identified by smoking cessation procedures	225	12.0%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	34	1.8%
Drug Abuse or Dependence	20	1.1%
History of Cardiac Arrest	****	****
History of Coronary Angioplasty or Bypass	107	5.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	15.9	12.1

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	15.9	12.1
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.2	5.2
Mean number of filled prescriptions	12.1	11.0
Mean number of generics dispensed	5.8	4.2
Mean number of unique drug classes dispensed	5.5	3.9

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1f. Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	****	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	13.9	0.0
Age	Number	Percent
0-17 years	****	****
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	****	****
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	****
Year		
2020	0	0.0%
2021	****	****
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%



Table 1f. Aggregated Characteristics of Lonafarnib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	1.0	0.0
Mean number of emergency room encounters	0.5	0.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	0.0	NaN
Mean number of filled prescriptions	5.5	0.0
Mean number of generics dispensed	3.5	0.0
Mean number of unique drug classes dispensed	3.5	0.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1g. Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	****	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	39.2	16.6
Age	Number	Percent
0-17 years	****	****
18-24 years	0	0.0%
25-40 years	****	****
41-64 years	****	****
≥ 65 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	****	****
White	****	****
Hispanic origin		
Yes	0	0.0%
No	****	****
Unknown	****	****
Year		
2020	0	0.0%
2021	****	****
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	****	****
Alzheimer's Disease and related conditions	****	****
Atrial Fibrillation	0	0.0%
Diabetes mellitus	****	****
Heart Failure	****	****
Hyperlipidemia	0	0.0%
Hypertension	****	****
Depression	****	****
Ischemic Heart Disease	****	****



Table 1g. Aggregated Characteristics of Lumasiran in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	****	****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	****	****
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	****	****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	****	****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	****	****
Drug Abuse or Dependence	****	****
History of Cardiac Arrest	****	****
History of Coronary Angioplasty or Bypass	0	0.0%

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	26.1	15.0
Mean number of emergency room encounters	0.6	0.3
Mean number of inpatient hospital encounters	0.6	0.0
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	17.4	28.4
Mean number of filled prescriptions	12.8	7.4
Mean number of generics dispensed	5.6	2.7
Mean number of unique drug classes dispensed	5.2	2.5

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1h. Aggregated Characteristics of Margetuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	189	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	65.1	10.5
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	****	****
41-64 years	****	****
≥ 65 years	111	58.7%
Sex		
Female	****	****
Male	****	****
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	****	****
Black or African American	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	58	30.7%
White	104	55.0%
Hispanic origin		
Yes	****	****
No	122	64.6%
Unknown	****	****
Year		
2020	0	0.0%
2021	99	52.4%
2022	90	47.6%
Health Characteristics		
Acute Myocardial Infarction	****	****
Alzheimer's Disease and related conditions	****	****
Atrial Fibrillation	****	****
Diabetes mellitus	25	13.2%
Heart Failure	49	25.9%
Hyperlipidemia	44	23.3%
Hypertension	76	40.2%
Depression	41	21.7%



Table 1h. Aggregated Characteristics of Margetuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	15	7.9%
Stroke/TIA	****	****
Breast Cancer	188	99.5%
Colorectal Cancer	****	****
Prostate Cancer	0	0.0%
Lung Cancer	14	7.4%
Endometrial Cancer	****	****
Acquired Hypothyroidism	33	17.5%
Anemia	93	49.2%
Asthma	****	****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	28	14.8%
COPD and Bronchiectasis	18	9.5%
Glaucoma	****	****
Osteoporosis	13	6.9%
Obesity: diagnosed or identified by weight management procedures	29	15.3%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	13	6.9%
Smoking: diagnosed or identified by smoking cessation procedures	37	19.6%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	****	****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	****	****

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	29.2	14.0
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.4	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.8	8.6
Mean number of filled prescriptions	19.4	14.2
Mean number of generics dispensed	8.2	4.7
Mean number of unique drug classes dispensed	7.7	4.3

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1i. Aggregated Characteristics of Naxitamab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	14	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	8.1	4.9
Age	Number	Percent
0-17 years	14	100.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	****	****
Male	****	****
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	****	****
White	****	****
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	14	100.0%
Year		
2020	0	0.0%
2021	****	****
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes mellitus	0	0.0%
Heart Failure	****	****
Hyperlipidemia	****	****
Hypertension	****	****
Depression	****	****
Ischemic Heart Disease	0	0.0%



Table 1i. Aggregated Characteristics of Naxitamab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	****	****
Anemia	11	78.6%
Asthma	****	****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	****	****
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	****	****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	42.9	9.1
Mean number of emergency room encounters	1.6	2.0
Mean number of inpatient hospital encounters	5.0	4.1
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	20.6	36.2
Mean number of filled prescriptions	26.9	17.6
Mean number of generics dispensed	11.8	5.6
Mean number of unique drug classes dispensed	10.9	5.3

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1j. Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	93	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	69.9	7.2
Age	Number	Percent
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	****	****
41-64 years	****	****
≥ 65 years	74	79.6%
Sex		
Female	51	54.8%
Male	42	45.2%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	****	****
Black or African American	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	****	****
White	50	53.8%
Hispanic origin		
Yes	****	****
No	59	63.4%
Unknown	****	****
Year		
2020	****	****
2021	50	53.8%
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	****	****
Diabetes mellitus	21	22.6%
Heart Failure	****	****
Hyperlipidemia	38	40.9%
Hypertension	57	61.3%
Depression	12	12.9%
Ischemic Heart Disease	17	18.3%



Table 1j. Aggregated Characteristics of Pralsetinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	****	****
Stroke/TIA	****	****
Breast Cancer	****	****
Colorectal Cancer	****	****
Prostate Cancer	****	****
Lung Cancer	65	69.9%
Endometrial Cancer	****	****
Acquired Hypothyroidism	30	32.3%
Anemia	27	29.0%
Asthma	****	****
Benign Prostatic Hyperplasia	13	14.0%
Chronic Kidney Disease	19	20.4%
COPD and Bronchiectasis	14	15.1%
Glaucoma	****	****
Osteoporosis	****	****
Obesity: diagnosed or identified by weight management procedures	15	16.1%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	****	****
Smoking: diagnosed or identified by smoking cessation procedures	35	37.6%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	****	****
Drug Abuse or Dependence	****	****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	****	****

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	24.3	12.0
Mean number of emergency room encounters	0.3	0.6
Mean number of inpatient hospital encounters	0.4	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.0	8.1
Mean number of filled prescriptions	18.4	12.8
Mean number of generics dispensed	8.6	4.9
Mean number of unique drug classes dispensed	8.0	4.5

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1k. Aggregated Characteristics of Relugolix in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Demographic Characteristics Mean Standard Deviation Age (years) 74.5 7.3 Age 17.45 7.3 Age 0.0% 0.0% 18-24 years 0 0.0% 25-40 years 0 0.0% 41-64 years 579 8.7% 2 65 years 6,091 91.3% Sex Female ************************************	Patient Characteristics	Number	Percent
Age Number Percent 0-17 years 0 0.0% 18-24 years 0 0.0% 25-40 years 0 0.0% 41-64 years 579 8.7% 2 65 years 6,091 91.3% Sex Female ************************************	Unique patients	6,670	N/A
Age Number Percent 0-17 years 0 0.0% 18-24 years 0 0.0% 25-40 years 0 0.0% 41-64 years 579 8.7% 2 65 years 6.091 91.3% Sex Female ***********************************	Demographic Characteristics	Mean	Standard Deviation
0-17 years 0 0.0% 18-24 years 0 0.0% 25-40 years 0 0.0% 41-64 years 579 8.7% 2 65 years 6,091 91.3% Sex Female ***********************************	Age (years)	74.6	7.3
18-24 years 0 0.0% 25-40 years 0 0.0% 41-64 years 579 8.7% 2 65 years 6,091 91.3% Sex Female ***********************************	Age	Number	Percent
25-40 years 0 0 0.0% 41-64 years 579 8.7% 2 65 years 6,091 91.3% Sex Female	0-17 years	0	0.0%
41-64 years 579 8.7% ≥ 65 years 66,091 91.3% 5Ex Female 6.0091 91.3% 5Ex Female 7.000	18-24 years	0	0.0%
2 65 years 6,091 91.3% Sex Female	25-40 years	0	0.0%
Sex Sex Female ****** ****** Male ****** ****** Race¹ ****** ******* American Indian or Alaska Native ****** ******* Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ****** ******* Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ***** ****** Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year ***** ****** 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% ***********************************	41-64 years	579	8.7%
Female ***** ***** Male ***** ***** Race¹ ***** ***** American Indian or Alaska Native ***** ****** Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ****** ****** Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin **** 1.0% Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 2220 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% *** *** Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% <tr< td=""><td>≥ 65 years</td><td>6,091</td><td>91.3%</td></tr<>	≥ 65 years	6,091	91.3%
Male ***** ***** Race¹ ****** ****** Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ******* ******* Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** 1.0% Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% *** *** 48.9% 2022 3,410 51.1% *** *** 4.2% *** *** 4.2% *** 1.3 *** 1.3 *** 1.3 *** <td< td=""><td>Sex</td><td></td><td></td></td<>	Sex		
Race t ****** ****** American Indian or Alaska Native ****** ****** Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ******* ******* Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ****** Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,260 48.9% 2022 3,240 51.1% Health Characteristics Actute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension	Female	****	****
American Indian or Alaska Native ****** ****** Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ******* ******* Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ****** Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 0 0.0% 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Actue Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension	Male	****	****
Asian 75 1.1% Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ******* ******** Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ******* Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year ************************************	Race ¹		
Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ******* ******* Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ******* Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year ************************************	American Indian or Alaska Native	****	****
Black or African American 714 10.7% Native Hawaiian or Other Pacific Islander ****** ****** Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ****** Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year ****** ****** 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Altrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Asian	75	1.1%
Native Hawaiian or Other Pacific Islander ****** ****** Unknown 1,350 20.2% White 4,507 67.6% Hispanic origin ****** ****** Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year ****** ****** 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Altrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Black or African American		
White 4,507 67.6% Hispanic origin 67 1.0% Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Native Hawaiian or Other Pacific Islander		
White 4,507 67.6% Hispanic origin 7es 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 7ear 7ear 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Unknown	1.350	20.2%
Hispanic origin Yes 67 1.0% No 5,009 75.1% Unknown 1,594 23.9% Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	White		
No 5,009 75.1% Unknown 1,594 23.9% Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Hispanic origin	,,	
No 5,009 75.1% Unknown 1,594 23.9% Year 3 8 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Yes	67	1.0%
Unknown 1,594 23.9% Year 0 0.0% 2020 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	No		
Year 2020 0 0.0% 2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Unknown		
2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Year	- /	
2021 3,260 48.9% 2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	2020	0	0.0%
2022 3,410 51.1% Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	2021		
Health Characteristics Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	2022		
Acute Myocardial Infarction 57 0.9% Alzheimer's Disease and related conditions 257 3.9% Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Health Characteristics	-7:	02127
Atrial Fibrillation 930 13.9% Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%		57	0.9%
Diabetes mellitus 1,570 23.5% Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Alzheimer's Disease and related conditions	257	3.9%
Heart Failure 789 11.8% Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Atrial Fibrillation	930	13.9%
Hyperlipidemia 3,062 45.9% Hypertension 3,664 54.9% Depression 722 10.8%	Diabetes mellitus	1,570	23.5%
Hypertension 3,664 54.9% Depression 722 10.8%	Heart Failure	789	11.8%
Depression 722 10.8%	Hyperlipidemia	3,062	45.9%
·	Hypertension	3,664	54.9%
	Depression	722	10.8%
		2,205	33.1%



Table 1k. Aggregated Characteristics of Relugolix in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	1,029	15.4%
Stroke/TIA	211	3.2%
Breast Cancer	231	3.5%
Colorectal Cancer	95	1.4%
Prostate Cancer	6,531	97.9%
Lung Cancer	68	1.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	437	6.6%
Anemia	1,453	21.8%
Asthma	191	2.9%
Benign Prostatic Hyperplasia	1,857	27.8%
Chronic Kidney Disease	1,230	18.4%
COPD and Bronchiectasis	480	7.2%
Glaucoma	325	4.9%
Osteoporosis	194	2.9%
Obesity: diagnosed or identified by weight management procedures	1,248	18.7%
Obesity: identified by weight management-related prescriptions	32	0.5%
Overweight	797	11.9%
Smoking: diagnosed or identified by smoking cessation procedures	1,719	25.8%
Smoking: identified by smoking-related prescriptions	18	0.3%
Alcohol Abuse or Dependence	146	2.2%
Drug Abuse or Dependence	117	1.8%
History of Cardiac Arrest	14	0.2%
History of Coronary Angioplasty or Bypass	783	11.7%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.6	13.3
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.5

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	18.6	13.3
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.6	7.0
Mean number of filled prescriptions	15.1	12.6
Mean number of generics dispensed	7.2	4.5
Mean number of unique drug classes dispensed	6.8	4.1

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1l. Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	6,834	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	62.7	15.1
Age	Number	Percent
0-17 years	72	1.1%
18-24 years	69	1.0%
25-40 years	577	8.4%
41-64 years	2,923	42.8%
≥ 65 years	3,193	46.7%
Sex		
Female	3,382	49.5%
Male	3,452	50.5%
Race ¹		
American Indian or Alaska Native	****	****
Asian	****	****
Black or African American	195	2.9%
Native Hawaiian or Other Pacific Islander	****	****
Unknown	4,871	71.3%
White	1,731	25.3%
Hispanic origin	,	
Yes	53	0.8%
No	15	0.2%
Unknown	6,766	99.0%
Year	-,	
2020	598	8.8%
2021	2,591	37.9%
2022	3,645	53.3%
Health Characteristics	2,5 .5	
Acute Myocardial Infarction	66	1.0%
Alzheimer's Disease and related conditions	360	5.3%
Atrial Fibrillation	691	10.1%
Diabetes mellitus	1,812	26.5%
Heart Failure	886	13.0%
Hyperlipidemia	2,163	31.7%
Hypertension	3,146	46.0%
Depression	1,207	17.7%
Ischemic Heart Disease	1,476	21.6%



Table 1l. Aggregated Characteristics of Remdesivir in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	1,034	15.1%
Stroke/TIA	171	2.5%
Breast Cancer	129	1.9%
Colorectal Cancer	56	0.8%
Prostate Cancer	110	1.6%
Lung Cancer	89	1.3%
Endometrial Cancer	****	****
Acquired Hypothyroidism	734	10.7%
Anemia	1,243	18.2%
Asthma	388	5.7%
Benign Prostatic Hyperplasia	287	4.2%
Chronic Kidney Disease	1,078	15.8%
COPD and Bronchiectasis	941	13.8%
Glaucoma	154	2.3%
Osteoporosis	180	2.6%
Obesity: diagnosed or identified by weight management procedures	1,921	28.1%
Obesity: identified by weight management-related prescriptions	76	1.1%
Overweight	492	7.2%
Smoking: diagnosed or identified by smoking cessation procedures	1,445	21.1%
Smoking: identified by smoking-related prescriptions	28	0.4%
Alcohol Abuse or Dependence	119	1.7%
Drug Abuse or Dependence	178	2.6%
History of Cardiac Arrest	11	0.2%
History of Coronary Angioplasty or Bypass	399	5.8%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
NA	44.0	12.0

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	11.9	13.8
Mean number of emergency room encounters	1.1	2.6
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	9.1
Mean number of filled prescriptions	16.6	18.1
Mean number of generics dispensed	7.1	5.9
Mean number of unique drug classes dispensed	6.6	5.4

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1m. Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	****	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	23.7	0.3
Age	Number	Percent
0-17 years	****	****
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	****	****
≥ 65 years	0	0.0%
Sex		
Female	****	****
Male	0	0.0%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	****	****
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	****	****
Year		
2020	0	0.0%
2021	0	0.0%
2022	****	****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	****	****
Hypertension	****	****
Depression	****	****
Ischemic Heart Disease	0	0.0%



Table 1m. Aggregated Characteristics of Setmelanotide in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	****	****
Anemia	0	0.0%
Asthma	****	****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	****	****
Obesity: identified by weight management-related prescriptions	****	****
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	****	****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	9.6	0.7
Mean number of emergency room encounters	0.2	0.0
Mean number of inpatient hospital encounters	0.0	NaN
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.2	2.5
Mean number of filled prescriptions	23.6	2.1
Mean number of generics dispensed	6.0	1.8
Mean number of unique drug classes dispensed	5.6	1.4

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1n. Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	3,422	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	61.5	8.7
Age	Number	Percent
0-17 years	****	****
18-24 years	0	0.0%
25-40 years	****	****
41-64 years	2,098	61.3%
≥ 65 years	1,203	35.2%
Sex		
Female	1,826	53.4%
Male	1,596	46.6%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	****	****
Black or African American	****	****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	2,368	69.2%
White	****	****
Hispanic origin		
Yes	****	****
No	****	****
Unknown	2,623	76.7%
Year	·	
2020	0	0.0%
2021	1,636	47.8%
2022	1,786	52.2%
Health Characteristics		
Acute Myocardial Infarction	****	****
Alzheimer's Disease and related conditions	52	1.5%
Atrial Fibrillation	125	3.7%
Diabetes mellitus	298	8.7%
Heart Failure	94	2.7%
Hyperlipidemia	778	22.7%
Hypertension	770	22.5%
Depression	339	9.9%
Ischemic Heart Disease		



Table 1n. Aggregated Characteristics of Tirbanibulin in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	404	11.8%
Stroke/TIA	27	0.8%
Breast Cancer	49	1.4%
Colorectal Cancer	****	****
Prostate Cancer	45	1.3%
Lung Cancer	****	****
Endometrial Cancer	****	****
Acquired Hypothyroidism	246	7.2%
Anemia	339	9.9%
Asthma	81	2.4%
Benign Prostatic Hyperplasia	126	3.7%
Chronic Kidney Disease	133	3.9%
COPD and Bronchiectasis	55	1.6%
Glaucoma	106	3.1%
Osteoporosis	78	2.3%
Obesity: diagnosed or identified by weight management procedures	345	10.1%
Obesity: identified by weight management-related prescriptions	30	0.9%
Overweight	271	7.9%
Smoking: diagnosed or identified by smoking cessation procedures	191	5.6%
Smoking: identified by smoking-related prescriptions	****	****
Alcohol Abuse or Dependence	40	1.2%
Drug Abuse or Dependence	44	1.3%
History of Cardiac Arrest	****	****
History of Coronary Angioplasty or Bypass	73	2.1%
Drug Abuse or Dependence History of Cardiac Arrest	44 ****	1.3%

Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	10.5	10.9
Mean number of emergency room encounters	0.1	0.4
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.2	3.5
Mean number of filled prescriptions	12.4	15.7
Mean number of generics dispensed	5.4	4.9
Mean number of unique drug classes dispensed	5.1	4.4

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 1o. Aggregated Characteristics of Vibegron in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Patient Characteristics	Number	Percent
Unique patients	41,892	N/A
Demographic Characteristics	Mean	Standard Deviation
Age (years)	74.0	11.1
Age	Number	Percent
0-17 years	****	****
18-24 years	****	****
25-40 years	642	1.5%
41-64 years	6,675	15.9%
≥ 65 years	34,467	82.3%
Sex		
Female	28,208	67.3%
Male	13,684	32.7%
Race ¹		
American Indian or Alaska Native	100	0.2%
Asian	864	2.1%
Black or African American	2,810	6.7%
Native Hawaiian or Other Pacific Islander	67	0.2%
Unknown	8,337	19.9%
White	29,714	70.9%
Hispanic origin		
Yes	785	1.9%
No	31,354	74.8%
Unknown	9,753	23.3%
Year	,	
2020	0	0.0%
2021	13,016	31.1%
2022	28,876	68.9%
Health Characteristics	·	
Acute Myocardial Infarction	229	0.5%
Alzheimer's Disease and related conditions	5,369	12.8%
Atrial Fibrillation	5,471	13.1%
Diabetes mellitus	12,228	29.2%
Heart Failure	5,281	12.6%
Hyperlipidemia	19,926	47.6%
Hypertension	25,349	60.5%
Depression		
	13,203	31.5%



Table 1o. Aggregated Characteristics of Vibegron in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Health Characteristics	Number	Percent
Rheumatoid Arthritis/Osteoarthritis	12,990	31.0%
Stroke/TIA	2,147	5.1%
Breast Cancer	1,633	3.9%
Colorectal Cancer	391	0.9%
Prostate Cancer	2,546	6.1%
Lung Cancer	368	0.9%
Endometrial Cancer	182	0.4%
Acquired Hypothyroidism	7,577	18.1%
Anemia	10,907	26.0%
Asthma	2,558	6.1%
Benign Prostatic Hyperplasia	6,540	15.6%
Chronic Kidney Disease	7,782	18.6%
COPD and Bronchiectasis	4,531	10.8%
Glaucoma	2,554	6.1%
Osteoporosis	3,462	8.3%
Obesity: diagnosed or identified by weight management procedures	11,207	26.8%
Obesity: identified by weight management-related prescriptions	418	1.0%
Overweight	4,531	10.8%
Smoking: diagnosed or identified by smoking cessation procedures	7,691	18.4%
Smoking: identified by smoking-related prescriptions	116	0.3%
Alcohol Abuse or Dependence	722	1.7%
Drug Abuse or Dependence	1,285	3.1%
History of Cardiac Arrest	40	0.1%
History of Coronary Angioplasty or Bypass	2,545	6.1%
Health Service Utilization Intensity Metrics	Mean	Standard Deviation
Mean number of ambulatory encounters	17.9	13.6
Mean number of emergency room encounters	0.4	1.2
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	8.0	15.5
	20.4	25.4

28.1

10.8

10.1

25.1

5.9

5.3

N/A: Not Applicable

Mean number of filled prescriptions

Mean number of generics dispensed

Mean number of unique drug classes dispensed

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

				Nun	nber of Dispensi	ngs by Days Sup	plied		
		1-30	Days	31-60) Days	61-90) Days	91+	Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings						
Ansuvimab	0	-	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-	-
Berotralstat	1,660	1,660	100.0%	0	0.0%	0	0.0%	0	0.0%
Copper	549	549	100.0%	0	0.0%	0	0.0%	0	0.0%
Gallium	2,023	2,023	100.0%	0	0.0%	0	0.0%	0	0.0%
Lonafarnib	14	14	100.0%	0	0.0%	0	0.0%	0	0.0%
Lumasiran	34	****	****	0	0.0%	****	****	0	0.0%
Margetuximab	888	888	100.0%	0	0.0%	0	0.0%	0	0.0%
Naxitamab	95	95	100.0%	0	0.0%	0	0.0%	0	0.0%
Pralsetinib	500	****	****	****	****	0	0.0%	0	0.0%
Relugolix	41,510	41,315	99.5%	****	****	118	0.3%	****	****
Remdesivir	12,199	12,199	100.0%	0	0.0%	0	0.0%	0	0.0%
Setmelanotide	14	14	100.0%	0	0.0%	0	0.0%	0	0.0%
Tirbanibulin	4,565	****	****	****	****	0	0.0%	0	0.0%
Vibegron	154,496	131,812	85.3%	****	****	18,372	11.9%	****	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

cder_mpl1r_wp242 Page 39 of 302



Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of Days Supplied by Dispensing Total Number Standard of Dispensings Minimum Q1 Median Q3 Maximum Deviation Mean Ansuvimab 0 Atoltivimab 0 Berotralstat 1,660 1 28 28 28 28 27.0 4.3 Copper 549 1 1 1 1 1 1.0 0.0 Gallium 2,023 1 1 1 1 1 1.0 0.0 Lonafarnib 14 22 30 30 30 30 29.4 2.1 1 90 22.3 Lumasiran 34 1 1 28 13.1 Margetuximab 888 1 1 2.9 1 1 21 1.4 Naxitamab 95 1 1 1 1 1 1.0 0.0 500 30 52 5.8 Pralsetinib 1 30 30 28.3 Relugolix 41,510 1 30 30 30 162 28.7 6.1 Remdesivir 12,199 1 1 1 1 3 1.0 0.0 Setmelanotide 14 4 27 28 30 30 24.5 9.3 5 5 Tirbanibulin 4,565 1 19 60 11.3 10.8 30 30 22.2 Vibegron 154,496 1 21 180 32.6

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

cder_mpl1r_wp242 Page 40 of 302



Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

	_	Number of Dispensings by Days Supplied							
		1-30) Days	31-6	0 Days	61-9	0 Days	91+	- Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Ansuvimab		-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-
Atoltivimab		-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-
Berotralstat	1,660	1,660	100.0%	0	NaN	0	NaN	0	NaN
Female	1,224	1,224	73.7%	0	NaN	0	NaN	0	NaN
Male	436	436	26.3%	0	NaN	0	NaN	0	NaN
Copper	549	549	100.0%	0	NaN	0	NaN	0	NaN
Female	293	293	53.4%	0	NaN	0	NaN	0	NaN
Male	256	256	46.6%	0	NaN	0	NaN	0	NaN
Gallium	2,023	2,023	100.0%	0	NaN	0	NaN	0	NaN
Female	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	0	NaN	0	NaN	0	NaN
Lonafarnib	14	14	100.0%	0	NaN	0	NaN	0	NaN
Female	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	0	NaN	0	NaN	0	NaN
Lumasiran	34	****	****	0	NaN	****	****	0	NaN
Female	18	****	****	0	NaN	****	****	0	NaN
Male	16	****	****	0	NaN	0	0.0%	0	NaN
Margetuximab	888	888	100.0%	0	NaN	0	NaN	0	NaN
Female	****	****	****	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp242 Page 41 of 302



Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

	_	Number of Dispensings by Days Supplied								
		1-3	0 Days	31-6	0 Days	61-9	61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	
Male	****	****	****	0	NaN	0	NaN	0	NaN	
Naxitamab	95	95	100.0%	0	NaN	0	NaN	0	NaN	
Female	40	40	42.1%	0	NaN	0	NaN	0	NaN	
Male	55	55	57.9%	0	NaN	0	NaN	0	NaN	
Pralsetinib	500	****	****	****	****	0	NaN	0	NaN	
Female	316	****	****	****	****	0	NaN	0	NaN	
Male	184	****	****	0	0.0%	0	NaN	0	NaN	
Relugolix	41,510	****	****	73	100.0%	118	100.0%	****	****	
Female	****	****	****	0	0.0%	0	0.0%	0	0.0%	
Male	****	****	****	73	100.0%	118	100.0%	****	****	
Remdesivir	12,199	12,199	100.0%	0	NaN	0	NaN	0	NaN	
Female	6,208	6,208	50.9%	0	NaN	0	NaN	0	NaN	
Male	5,991	5,991	49.1%	0	NaN	0	NaN	0	NaN	
Setmelanotide	14	14	100.0%	0	NaN	0	NaN	0	NaN	
Female	14	14	100.0%	0	NaN	0	NaN	0	NaN	
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	

cder_mpl1r_wp242 Page 42 of 302



Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

	_	Number of Dispensings by Days Supplied							
		1-30 Days			31-60 Days		61-90 Days		- Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Tirbanibulin	4,565	****	****	****	****	0	NaN	0	NaN
Female	2,386	****	****	0	0.0%	0	NaN	0	NaN
Male	2,179	****	****	****	****	0	NaN	0	NaN
Vibegron	154,496	131,812	100.0%	****	****	18,372	100.0%	****	****
Female	105,707	91,138	69.1%	****	****	11,801	64.2%	****	****
Male	48,789	40,674	30.9%	****	****	6,571	35.8%	****	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 43 of 302



Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Days Supplied by Dispensing Total Number Standard of Dispensings Minimum Q1 Median Q3 Maximum Mean Deviation **Ansuvimab** 0 Female 0 Male 0 **Atoltivimab** 0 Female 0 Male 0 Berotralstat 1,660 1 28 28 28 28 27.0 4.3 Female 1,224 1 28 28 28 28 26.9 4.3 28 28 Male 436 1 28 28 27.0 4.2 1 1 0.0 Copper 549 1 1 1 1.0 Female 293 1 1 1 1 1 1.0 0.0 Male 256 1 1 1 1 1 1.0 0.0 Gallium 2,023 1 1 1 1 1 1.0 0.0 **** 1 1 1 1 1 Female 1.0 0.0 **** Male 1 1 1 1 1 1.0 0.0 Lonafarnib 14 22 30 30 30 30 29.4 2.1 **** 30 30 30 0.0 Female 30 30 30.0 **** 22 30 30 Male 30 30 29.3 2.4 1 28 90 22.3 Lumasiran 34 1 1 13.1 Female 18 1 1 1 28 90 15.8 27.9 Male 16 1 1 1 30 30 10.1 13.9

cder_mpl1r_wp242 Page 44 of 302

1

1

1

1

1

1

21

21

1

1.4

1.4

1.0

2.9

2.9

0.0

Margetuximab

Female

Male

888

1

1

1

1

1

1



Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Days Supplied by Dispensing Standard **Total Number** of Dispensings Minimum Q1 Median Q3 Maximum Mean Deviation **Naxitamab** 95 1 1 1 1.0 0.0 1 1 Female 40 1 1 1 1 1 0.0 1.0 Male 55 1 1 1 1 1 1.0 0.0 Pralsetinib 500 1 30 30 30 52 28.3 5.8 30 30 52 28.4 5.7 Female 316 1 30 Male 184 1 30 30 30 30 28.0 6.1 Relugolix 41.510 1 30 30 30 162 28.7 6.1 **** Female 30 30 30 30 30 30.0 0.0 **** Male 1 30 30 30 162 28.7 6.1 Remdesivir 12,199 1 1 1 1 3 1.0 0.0 Female 1 1 1 1 3 1.0 0.0 6,208 2 Male 5,991 1 1 1 1 1.0 0.0 Setmelanotide 14 4 27 28 30 30 24.5 9.3 4 14 27 28 30 30 24.5 9.3 Female Male 0 NaN NaN NaN NaN NaN NaN NaN **Tirbanibulin** 4,565 1 5 5 19 60 11.3 10.8 5 5 1 30 Female 2,386 28 11.5 10.9 5 5 Male 2,179 1 14 60 11.1 10.6 21 Vibegron 154,496 1 30 30 180 32.6 22.2 Female 1 18 30 30 180 105,707 32.0 21.8 48,789 1 28 30 30 120 34.1 23.0 Male

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 45 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	_			Nur	nber of Dispensi	ngs by Days Sup	olied		
		1-30	Days	31-60) Days	61-90) Days	91+	Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings						
Ansuvimab		-	-	-	-	-	-	-	-
0-17 years		-	-	-	-	-	-	-	-
18-24 years		-	-	-	-	-	-	-	-
25-40 years		-	-	-	-	-	-	-	-
41-64 years		-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-
Atoltivimab		-	-	-	-	-	-	-	-
0-17 years		-	-	-	-	-	-	-	-
18-24 years		-	-	-	-	-	-	-	-
25-40 years		-	-	-	-	-	-	-	-
41-64 years		-	-	-	-	-	-	-	-
≥ 65 years		-	-	-	-	-	-	-	-
Berotralstat	1,660	1,660	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	40	40	2.4%	0	NaN	0	NaN	0	NaN
18-24 years	168	168	10.1%	0	NaN	0	NaN	0	NaN
25-40 years	253	253	15.2%	0	NaN	0	NaN	0	NaN
41-64 years	705	705	42.5%	0	NaN	0	NaN	0	NaN
≥ 65 years	494	494	29.8%	0	NaN	0	NaN	0	NaN
Copper	549	549	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN

cder_mpl1r_wp242 Page 46 of 302



Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	_	Number of Dispensings by Days Supplied										
		1-30	Days	31-60) Days	61-90) Days	91+	Days			
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings			
41-64 years	302	302	55.0%	0	NaN	0	NaN	0	NaN			
≥ 65 years	199	199	36.2%	0	NaN	0	NaN	0	NaN			
Gallium	2,023	2,023	100.0%	0	NaN	0	NaN	0	NaN			
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
41-64 years	157	157	7.8%	0	NaN	0	NaN	0	NaN			
≥ 65 years	1,866	1,866	92.2%	0	NaN	0	NaN	0	NaN			
Lonafarnib	14	14	100.0%	0	NaN	0	NaN	0	NaN			
0-17 years	14	14	100.0%	0	NaN	0	NaN	0	NaN			
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			
Lumasiran	34	****	****	0	NaN	****	****	0	NaN			
0-17 years	****	****	****	0	NaN	0	0.0%	0	NaN			
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN			
25-40 years	15	15	46.9%	0	NaN	0	0.0%	0	NaN			
41-64 years	****	****	****	0	NaN	****	****	0	NaN			
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN			
Margetuximab	888	888	100.0%	0	NaN	0	NaN	0	NaN			
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN			

cder_mpl1r_wp242 Page 47 of 302



Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	<u>-</u>			Nur	nber of Dispensii	ngs by Days Supp	olied		
		1-30	Days	31-60) Days	61-90) Days	91+	Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings						
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	19	19	2.1%	0	NaN	0	NaN	0	NaN
41-64 years	328	328	36.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	541	541	60.9%	0	NaN	0	NaN	0	NaN
Naxitamab	95	95	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	95	95	100.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Pralsetinib	500	****	****	****	****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	148	148	29.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	****	****	****	****	****	0	NaN	0	NaN
Relugolix	41,510	41,315	100.0%	****	****	118	100.0%	****	****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	3,653	3,642	8.8%	****	****	****	****	0	0.0%
≥ 65 years	37,857	37,673	91.2%	****	****	****	****	****	****

cder_mpl1r_wp242 Page 48 of 302



Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	_			Nur	nber of Dispensi	ngs by Days Sup	olied		
		1-30	Days	31-60) Days	61-90) Days	91+	Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings						
Remdesivir	12,199	12,199	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	147	147	1.2%	0	NaN	0	NaN	0	NaN
18-24 years	131	131	1.1%	0	NaN	0	NaN	0	NaN
25-40 years	982	982	8.0%	0	NaN	0	NaN	0	NaN
41-64 years	4,892	4,892	40.1%	0	NaN	0	NaN	0	NaN
≥ 65 years	6,047	6,047	49.6%	0	NaN	0	NaN	0	NaN
Setmelanotide	14	14	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	****	****	****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Tirbanibulin	4,565	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	2,692	****	****	****	****	0	NaN	0	NaN
≥ 65 years	1,722	****	****	****	****	0	NaN	0	NaN
Vibegron	154,496	131,812	100.0%	****	****	18,372	100.0%	****	****
0-17 years	23	****	****	****	****	0	0.0%	0	0.0%
18-24 years	304	****	****	****	****	34	0.2%	0	0.0%
25-40 years	2,329	2,080	1.6%	****	****	181	1.0%	****	****

cder_mpl1r_wp242 Page 49 of 302



Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	_			Nur	nber of Dispensi	ngs by Days Supp	olied		
		1-30	Days	31-60) Days	61-90) Days	91+	Days
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings						
41-64 years	25,555	22,124	16.8%	****	****	2,709	14.7%	****	****
≥ 65 years	126,285	107,322	81.4%	****	****	15,448	84.1%	****	****

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 50 of 302



Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing **Total Number** Standard of Dispensings Median Maximum Minimum Q1 Q3 Mean Deviation **Ansuvimab** 0 0-17 years 0 0 18-24 years 25-40 years 0 41-64 years 0 ≥ 65 years 0 0 **Atoltivimab** 0 0-17 years 18-24 years 0 25-40 years 0 41-64 years 0 ≥ 65 years 0 **Berotralstat** 1,660 1 4.3 28 28 28 28 27.0 0-17 years 40 7 28 28 28 28 26.8 4.7 28 28 28 28 26.9 18-24 years 168 1 4.6 25-40 years 28 28 28 26.7 253 1 28 4.9 41-64 years 28 705 1 28 28 28 27.0 4.2 494 3 28 28 28 28 27.1 3.9 ≥ 65 years Copper 549 1 1 1 1 1 1.0 0.0 **** 0-17 years 1 1 1 1 1 1.0 NaN 18-24 years 1 1 1 1 1 1.0 0.0 1 1 1 1 25-40 years 1 1.0 0.0 41-64 years 302 1 1 1 1 1 1.0 0.0

cder_mpl1r_wp242 Page 51 of 302

1

1

1

1.0

0.0

1

≥ 65 years

199

1



Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing **Total Number** Standard Median of Dispensings Minimum Q1 Q3 Maximum Mean Deviation Gallium 2,023 1 1 1 1 1 1.0 0.0 0 NaN NaN NaN 0-17 years NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 157 1 1 1 1 1 1.0 0.0 ≥ 65 years 1,866 1.0 0.0 1 1 1 1 1 Lonafarnib 14 22 30 30 30 30 29.4 2.1 22 30 30 30 30 0-17 years 14 29.4 2.1 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 1 1 1 22.3 Lumasiran 34 28 90 13.1 **** 0-17 years 1 1 1 1 30 5.8 11.8 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 15 1 1 1 30 30 9.7 13.2 41-64 years 1 1 1 28 90 20.5 31.7 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN Margetuximab 888 1 1 1 1 21 1.4 2.9 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 19 1 1 1 1 1 1.0 0.0 41-64 years 328 1 1 1 1 1 1.0 0.0 ≥ 65 years 541 1 1 1 1 21 1.7 3.7

cder_mpl1r_wp242 Page 52 of 302



Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing **Total Number** Standard of Dispensings Minimum Q1 Median Q3 Maximum Mean Deviation **Naxitamab** 1 1 1 1 1 1.0 0.0 95 95 1 1 1 1 1 0.0 0-17 years 1.0 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN 1 **Pralsetinib** 500 30 30 30 **52** 28.3 5.8 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 30 30 30 30 30 30.0 0.0 **** 41-64 years 1 30 30 30 30 28.0 5.8 ≥ 65 years 348 30 30 30 52 28.4 5.9 1 1 30 30 30 6.1 Relugolix 41,510 162 28.7 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 3,653 1 30 30 30 90 28.4 5.9 30 30 28.7 ≥ 65 years 37,857 1 30 162 6.1 Remdesivir 12,199 1 1 1 1 3 1.0 0.0 0-17 years 147 1 1 1 1 1 1.0 0.0 1 1 1 1 0.0 18-24 years 131 1 1.0 25-40 years 982 1 1 1 1 1 1.0 0.0 41-64 years 4,892 1 1 1 1 3 1.0 0.0 ≥ 65 years 6,047 1 1 1 1 2 1.0 0.0

cder_mpl1r_wp242 Page 53 of 302



Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing **Total Number** Standard of Dispensings Minimum Q1 Median Q3 Maximum Mean Deviation Setmelanotide 4 27 28 30 30 24.5 9.3 14 **** 4 27 28 30 30 24.2 9.6 0-17 years 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN **** 28 28 41-64 years 28 28 28 28.0 NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN Tirbanibulin 5 5 4,565 1 19 60 11.3 10.8 **** 5 5 5 5 5 5.0 0.0 0-17 years 0 18-24 years NaN NaN NaN NaN NaN NaN NaN **** 5 5 5 25-40 years 5 30 10.6 10.4 41-64 years 2,692 1 5 5 5 35 9.3 9.4 1,722 5 5 30 60 12.0 ≥ 65 years 1 14.5 1 22.2 Vibegron 154,496 21 30 30 180 32.6 0-17 years 23 4 18 30 30 54 27.6 11.0 20.0 18-24 years 304 2 30 30 30 90 34.4 25-40 years 2,329 1 30 30 30 105 30.9 18.6 41-64 years 25,555 1 25 30 30 180 32.1 21.0 126,285 20 30 30 120 32.8 22.5 ≥ 65 years 1

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 54 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

			Number of Patients by Cumulative Treatment Episode Duration											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days			
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients			
Ansuvimab	0	-	-	-	-	-	-	-	-	-	-			
Atoltivimab	0	-	-	-	-	-	-	-	-	-	-			
Berotralstat	191	19	9.9%	33	17.3%	94	49.2%	45	23.6%	0	0.0%			
Copper	506	506	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%			
Gallium	1,879	1,879	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%			
Lonafarnib	****	0	0.0%	****	****	****	****	0	0.0%	0	0.0%			
Lumasiran	****	****	****	0	0.0%	****	****	0	0.0%	0	0.0%			
Margetuximab	189	****	****	****	****	****	****	0	0.0%	0	0.0%			
Naxitamab	14	14	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%			
Pralsetinib	93	****	****	26	28.0%	37	39.8%	****	****	0	0.0%			
Relugolix	6,670	924	13.9%	1,497	22.4%	3,442	51.6%	807	12.1%	0	0.0%			
Remdesivir	6,834	6,834	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%			
Setmelanotide	****	****	****	****	****	****	****	0	0.0%	0	0.0%			
Tirbanibulin	3,422	3,164	92.5%	219	6.4%	39	1.1%	0	0.0%	0	0.0%			
Vibegron	41,892	11,378	27.2%	11,997	28.6%	16,814	40.1%	1,703	4.1%	0	0.0%			

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

cder_mpl1r_wp242 Page 55 of 302



Table 3b. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of Cumulative Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean Ansuvimab 0 0 Atoltivimab Berotralstat 191 4 84 210 364 638 234.3 172.5 Copper 506 1 1 1 1 3 1.1 0.3 Gallium 1,879 1 1 1 1 5 1.1 0.3 **** 90 90 322 206.0 Lonafarnib 206 322 164.0 **** 7 Lumasiran 1 2 30 258 44.6 83.2 2 6 6.7 Margetuximab 189 1 4 148 15.0 Naxitamab 14 2 2 11 19 6.8 5.5 Pralsetinib 93 1 48 105 204 576 151.9 146.9 Relugolix 6,670 1 61 147 260 691 178.3 138.3 Remdesivir 1 1 1 3 1.8 1.0 6,834 11 **** Setmelanotide 28 33 62 70 150 68.6 49.0 5 5 Tirbanibulin 3,422 1 22 265 15.1 20.9 41,892 30 90 180 594 120.4 107.5 Vibegron 1

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 56 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

			Number of Patients by Cumulative Treatment Episode Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days			
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients			
Ansuvimab		-	-	-	-	-	-	-	-	-	-			
Female		-	-	-	-	-	-	-	-	-	-			
Male		-	-	-	-	-	-	-	-	-	-			
Atoltivimab		-	-	-	-	-	-	-	-	-	-			
Female		-	-	-	-	-	-	-	-	-	-			
Male		-	-	-	-	-	-	-	-	-	-			
Berotralstat	191	19	100.0%	33	100.0%	94	100.0%	45	100.0%	0	NaN			
Female	142	****	****	****	****	74	78.7%	32	71.1%	0	NaN			
Male	49	****	****	****	****	20	21.3%	13	28.9%	0	NaN			
Copper	506	506	100.0%	0	NaN	0	NaN	0	NaN	0	NaN			
Female	271	271	53.6%	0	NaN	0	NaN	0	NaN	0	NaN			
Male	235	235	46.4%	0	NaN	0	NaN	0	NaN	0	NaN			
Gallium	1,879	1,879	100.0%	0	NaN	0	NaN	0	NaN	0	NaN			
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Lonafarnib	****	0	NaN	****	****	****	****	0	NaN	0	NaN			
Female	****	0	NaN	****	****	0	0.0%	0	NaN	0	NaN			
Male	****	0	NaN	0	0.0%	****	****	0	NaN	0	NaN			
Lumasiran	****	****	****	0	NaN	****	****	0	NaN	0	NaN			
Female	****	****	****	0	NaN	****	****	0	NaN	0	NaN			
Male	****	****	****	0	NaN	****	****	0	NaN	0	NaN			
Margetuximab	189	****	****	****	****	****	****	0	NaN	0	NaN			

cder_mpl1r_wp242 Page 57 of 302



Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

		Number of Patients by Cumulative Treatment Episode Duration 1.20 Page 21.00 Page 21.00 Page 22.00 Page 23.00											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
Female	****	****	****	****	****	****	****	0	NaN	0	NaN		
Male	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN		
Naxitamab	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
Pralsetinib	93	****	****	26	100.0%	37	100.0%	****	****	0	NaN		
Female	51	****	****	****	****	17	45.9%	****	****	0	NaN		
Male	42	****	****	****	****	20	54.1%	****	****	0	NaN		
Relugolix	6,670	924	100.0%	1,497	100.0%	3,442	100.0%	807	100.0%	0	NaN		
Female	****	0	0.0%	****	****	0	0.0%	0	0.0%	0	NaN		
Male	****	924	100.0%	****	****	3,442	100.0%	807	100.0%	0	NaN		
Remdesivir	6,834	6,834	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
Female	3,382	3,382	49.5%	0	NaN	0	NaN	0	NaN	0	NaN		
Male	3,452	3,452	50.5%	0	NaN	0	NaN	0	NaN	0	NaN		
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN		
Female	****	****	****	****	****	****	****	0	NaN	0	NaN		
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
Tirbanibulin	3,422	3,164	100.0%	219	100.0%	39	100.0%	0	NaN	0	NaN		
Female	1,826	1,697	53.6%	102	46.6%	27	69.2%	0	NaN	0	NaN		
Male	1,596	1,467	46.4%	117	53.4%	12	30.8%	0	NaN	0	NaN		

cder_mpl1r_wp242 Page 58 of 302



Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

				Nur	nber of Patien	its by Cumulat	ive Treatment	t Episode Dura	tion		
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients								
Vibegron	41,892	11,378	100.0%	11,997	100.0%	16,814	100.0%	1,703	100.0%	0	NaN
Female	28,208	7,752	68.1%	8,083	67.4%	11,242	66.9%	1,131	66.4%	0	NaN
Male	13,684	3,626	31.9%	3,914	32.6%	5,572	33.1%	572	33.6%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242



Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, Days Total Number Standard of Patients Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 -Female 0 Male 0 **Atoltivimab** 0 _ Female 0 Male 0 191 84 Berotralstat 4 210 364 638 234.3 172.5 Female 142 4 84 205 364 638 232.2 167.0 Male 49 5 57 222 366 614 240.2 189.2 506 1 1 1 1 3 Copper 1.1 0.3 1 1 3 Female 271 1 1 1.1 0.3 Male 235 2 1.1 0.3 1 1 1 1 1 1 5 Gallium 1,879 1 1 1.1 0.3 **** 1 1 Female 1 1 1 1.0 0.0 **** Male 1 1 5 1.1 0.3 1 1 **** 90 90 206 322 206.0 Lonafarnib 322 164.0 **** Female 90 90 90 90 90 90.0 NaN **** Male 322 322 322 322 322 322.0 NaN **** 1 2 7 30 258 44.6 Lumasiran 83.2 **** Female 2 5 5 15 258 57.0 112.5 **** Male 2 8 30 120 32.2 50.5 1 1 2 4 6 148 6.7 15.0 Margetuximab 189 **** 1 2 6 Female 4 148 6.7 15.1 Male 2 2 2 2 2 2.0 NaN

cder_mpl1r_wp242 Page 60 of 302



Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, Days **Total Number** Standard of Patients Minimum Median Deviation Q1 Q3 Maximum Mean **Naxitamab** 14 2 2 4 11 19 6.8 5.5 **** 2 2 7 12 6.7 4.5 Female 11 **** Male 2 3 3 12 19 6.9 6.5 Pralsetinib 93 1 48 105 204 576 151.9 146.9 Female 51 4 60 105 300 576 176.2 165.5 Male 42 1 30 99 166 535 122.5 115.9 1 Relugolix 6,670 61 147 260 691 178.3 138.3 **** 60 60 60.0 Female 60 60 60 NaN **** Male 1 61 147 260 691 178.3 138.3 1 3 Remdesivir 6,834 1 1 11 1.8 1.0 1 3 Female 3,382 1 1 10 1.8 1.0 Male 3 1.7 3.452 1 1 1 11 1.0 **** Setmelanotide 28 33 62 70 150 68.6 49.0 **** Female 28 33 62 70 150 68.6 49.0 Male 0 NaN NaN NaN NaN NaN NaN NaN 5 5 Tirbanibulin 3,422 1 22 265 15.1 20.9 5 5 Female 1,826 1 20 265 15.1 22.0 5 25 232 Male 1,596 1 5 15.2 19.5 1 30 90 120.4 Vibegron 41,892 180 594 107.5 Female 28,208 1 30 90 180 585 119.8 107.5 13,684 30 594 121.6 107.5 Male 1 90 180

cder mpl1r wp242 Page 61 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.



Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

			Number of Patients by Cumulative Treatment Episode Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
Ansuvimab		-	-	-	-	-	-	-	-	-	-		
0-17 years		-	-	-	-	-	-	-	-	-	-		
18-24 years		-	-	-	-	-	-	-	-	-	-		
25-40 years		-	-	-	-	-	-	-	-	-	-		
41-64 years		-	-	-	-	-	-	-	-	-	-		
≥ 65 years		-	-	-	-	-	-	-	-	-	-		
Atoltivimab		-	-	-	-	-	-	-	-	-	-		
0-17 years		-	-	-	-	-	-	-	-	-	-		
18-24 years		-	-	-	-	-	-	-	-	-	-		
25-40 years		-	-	-	-	-	-	-	-	-	-		
41-64 years		-	-	-	-	-	-	-	-	-	-		
≥ 65 years		-	-	-	-	-	-	-	-	-	-		
Berotralstat	191	19	100.0%	33	100.0%	94	100.0%	45	100.0%	0	NaN		
0-17 years	****	****	****	0	0.0%	****	****	****	****	0	NaN		
18-24 years	****	0	0.0%	****	****	****	****	****	****	0	NaN		
25-40 years	33	****	****	****	****	****	****	****	****	0	NaN		
41-64 years	82	****	****	****	****	44	46.8%	18	40.0%	0	NaN		
≥ 65 years	55	****	****	****	****	21	22.3%	16	35.6%	0	NaN		
Copper	506	506	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		

cder_mpl1r_wp242 Page 62 of 302



Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

			Number of Patients by Cumulative Treatment Episode Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days									
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
41-64 years	277	277	54.7%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	183	183	36.2%	0	NaN	0	NaN	0	NaN	0	NaN	
Gallium	1,879	1,879	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
41-64 years	152	152	8.1%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	1,727	1,727	91.9%	0	NaN	0	NaN	0	NaN	0	NaN	
Lonafarnib	****	0	NaN	****	****	****	****	0	NaN	0	NaN	
0-17 years	****	0	NaN	****	****	****	****	0	NaN	0	NaN	
18-24 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN	
25-40 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN	
41-64 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN	
≥ 65 years	0	0	NaN	0	0.0%	0	0.0%	0	NaN	0	NaN	
Lumasiran	****	****	****	0	NaN	****	****	0	NaN	0	NaN	
0-17 years	****	****	****	0	NaN	0	0.0%	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN	
25-40 years	****	****	****	0	NaN	****	****	0	NaN	0	NaN	
41-64 years	****	****	****	0	NaN	****	****	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	NaN	0	0.0%	0	NaN	0	NaN	
Margetuximab	189	****	****	****	****	****	****	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	

cder_mpl1r_wp242 Page 63 of 302



Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

			Number of Patients by Cumulative Treatment Episode Duration										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
25-40 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN		
41-64 years	72	72	38.9%	0	0.0%	0	0.0%	0	NaN	0	NaN		
≥ 65 years	****	****	****	****	****	****	****	0	NaN	0	NaN		
Naxitamab	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
0-17 years	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN		
Pralsetinib	93	****	****	26	100.0%	37	100.0%	****	****	0	NaN		
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
25-40 years	****	0	0.0%	0	0.0%	****	****	0	0.0%	0	NaN		
41-64 years	****	****	****	****	****	****	****	****	****	0	NaN		
≥ 65 years	74	****	****	****	****	****	****	****	****	0	NaN		
Relugolix	6,670	924	100.0%	1,497	100.0%	3,442	100.0%	807	100.0%	0	NaN		
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN		
41-64 years	579	80	8.7%	118	7.9%	315	9.2%	66	8.2%	0	NaN		
≥ 65 years	6,091	844	91.3%	1,379	92.1%	3,127	90.8%	741	91.8%	0	NaN		



Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

			Number of Patients by Cumulative Treatment Episode Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
Remdesivir	6,834	6,834	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
0-17 years	72	72	1.1%	0	NaN	0	NaN	0	NaN	0	NaN		
18-24 years	69	69	1.0%	0	NaN	0	NaN	0	NaN	0	NaN		
25-40 years	577	577	8.4%	0	NaN	0	NaN	0	NaN	0	NaN		
41-64 years	2,923	2,923	42.8%	0	NaN	0	NaN	0	NaN	0	NaN		
≥ 65 years	3,193	3,193	46.7%	0	NaN	0	NaN	0	NaN	0	NaN		
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN		
0-17 years	****	0	0.0%	****	****	****	****	0	NaN	0	NaN		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
41-64 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN		
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
Tirbanibulin	3,422	3,164	100.0%	219	100.0%	39	100.0%	0	NaN	0	NaN		
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN		
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN		
25-40 years	****	****	****	****	****	0	0.0%	0	NaN	0	NaN		
41-64 years	2,098	1,994	63.0%	****	****	****	****	0	NaN	0	NaN		
≥ 65 years	1,203	1,057	33.4%	****	****	****	****	0	NaN	0	NaN		

cder_mpl1r_wp242 Page 65 of 302



Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

				Nun	nber of Patien	ts by Cumulat	ive Treatment	t Episode Dura	tion		
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Patients	Number of Patients	Percent of Total Patients								
Vibegron	41,892	11,378	100.0%	11,997	100.0%	16,814	100.0%	1,703	100.0%	0	NaN
0-17 years	****	****	****	****	****	****	****	0	0.0%	0	NaN
18-24 years	****	****	****	****	****	****	****	****	****	0	NaN
25-40 years	642	****	****	198	1.7%	248	1.5%	****	****	0	NaN
41-64 years	6,675	1,651	14.5%	1,908	15.9%	2,822	16.8%	294	17.3%	0	NaN
≥ 65 years	34,467	9,521	83.7%	9,854	82.1%	13,705	81.5%	1,387	81.4%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 66 of 302



Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, Days

	Total Number					Episode Buration, Bu	•	Standard
	of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Ansuvimab	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Berotralstat	191	4	84	210	364	638	234.3	172.5
0-17 years	****	28	91	147	252	554	214.4	206.9
18-24 years	****	46	154	240	408	535	282.3	165.4
25-40 years	33	4	84	192	275	532	204.3	143.7
41-64 years	82	7	91	201	348	638	232.3	169.7
≥ 65 years	55	4	56	196	382	614	243.0	192.7
Copper	506	1	1	1	1	3	1.1	0.3
0-17 years	****	1	1	1	1	1	1.0	NaN
18-24 years	****	1	1	1	1	1	1.0	0.0
25-40 years	****	1	1	1	1	2	1.1	0.2
41-64 years	277	1	1	1	1	3	1.1	0.3
≥ 65 years	183	1	1	1	1	2	1.1	0.3

cder_mpl1r_wp242 Page 67 of 302



Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean Gallium 1.879 1 1 1 1 5 1.1 0.3 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 152 1 1 1 2 1.0 0.2 1 5 ≥ 65 years 1,727 1 1 1 1 1.1 0.3 **** 90 90 322 206.0 Lonafarnib 206 322 164.0 **** 0-17 years 90 90 206 322 322 206.0 164.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN ≥ 65 years NaN NaN NaN NaN NaN NaN NaN **** Lumasiran 1 2 7 30 258 44.6 83.2 **** 5 5 0-17 years 18 30 30 17.5 17.7 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 2 5 68 25-40 years 12 120 36.3 56.1 **** 41-64 years 1 2 4 132 258 66.5 127.7 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 1 2 4 6 Margetuximab 189 148 6.7 15.0 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 1 2 3 3 8 3.2 2.5 **** 5 41-64 years 1 3 4 23 4.6 3.7 1 2 4 7 148 8.2 19.3

Page 68 of 302 cder mpl1r wp242

≥ 65 years

111



Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, Days Standard **Total Number** of Patients Minimum Median Q3 Maximum Deviation Q1 Mean 2 **Naxitamab** 14 2 4 11 19 6.8 5.5 0-17 years 14 2 2 4 19 6.8 5.5 11 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 93 1 48 576 Pralsetinib 105 204 151.9 146.9 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 120 120 120 120 120 120.0 NaN **** 41-64 years 30 60 149 412 576 230.3 181.9 ≥ 65 years 74 1 30 79 167 541 133.3 132.8 1 Relugolix 6,670 61 147 260 691 178.3 138.3 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 579 1 68 150 265 614 179.3 137.6 691 138.3 ≥ 65 years 6,091 1 61 145 260 178.2 1 1 1 3 Remdesivir 6,834 11 1.8 1.0 0-17 years 72 1 1 2 3 5 2.0 1.0 69 1 1 3 5 1.2 18-24 years 1 1.9 3 25-40 years 577 1 1 1 6 1.7 1.0 41-64 years 2,923 1 1 1 2 6 1.7 1.0

cder mpl1r wp242 Page 69 of 302

1

3

11

1.9

1.1

1

3.193

≥ 65 years

1



Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, Days Total Number Standard of Patients Median Maximum Deviation Minimum Q1 Q3 Mean **** Setmelanotide 28 33 62 70 150 68.6 49.0 **** 48 66 0-17 years 33 110 150 78.8 50.1 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN **** 28 28 28 28 28 28.0 41-64 years NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN 1 5 Tirbanibulin 3,422 5 22 265 15.1 20.9 **** 0-17 years 10 10.0 10 10 10 10 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 5 25-40 years 5 5 18 65 13.2 14.8 41-64 years 1 5 5 10 120 12.0 13.4 2.098 5 5 30 265 20.8 29.2 ≥ 65 years 1,203 1 Vibegron 41,892 1 30 90 180 594 120.4 107.5 **** 0-17 years 30 30 50 86 150 63.4 42.0 **** 2 18-24 years 30 121 450 106.8 94.8 81 25-40 years 642 2 30 82 153 517 112.2 102.2 41-64 years 6,675 1 31 90 180 594 122.9 107.3 1 30 90 593 107.6 ≥ 65 years 34,467 180 120.1

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 70 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

					Numbei	of Treatment	Episodes by	Duration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes								
Ansuvimab	0	-	-	-	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-	-	-	-
Berotralstat	392	162	41.3%	95	24.2%	102	26.0%	33	8.4%	0	0.0%
Copper	549	549	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gallium	2,023	2,023	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lonafarnib	12	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
Lumasiran	31	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
Margetuximab	870	****	****	****	****	****	****	0	0.0%	0	0.0%
Naxitamab	95	95	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pralsetinib	215	129	60.0%	53	24.7%	****	****	****	****	0	0.0%
Relugolix	13,734	6,064	44.2%	3,936	28.7%	3,422	24.9%	312	2.3%	0	0.0%
Remdesivir	7,038	7,038	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Setmelanotide	****	****	****	****	****	****	****	0	0.0%	0	0.0%
Tirbanibulin	4,293	4,183	97.4%	****	****	****	****	0	0.0%	0	0.0%
Vibegron	81,661	45,938	56.3%	23,586	28.9%	11,530	14.1%	607	0.7%	0	0.0%

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

cder_mpl1r_wp242 Page 71 of 302



Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

	Number of Treatment Episodes by Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days										
		1-30	Days	31-90	Days	91-365	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes								
Ansuvimab		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Atoltivimab		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Berotralstat	392	162	100.0%	95	100.0%	102	100.0%	33	100.0%	0	NaN
Female	298	124	76.5%	****	****	78	76.5%	****	****	0	NaN
Male	94	38	23.5%	****	****	24	23.5%	****	****	0	NaN
Copper	549	549	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	293	293	53.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	256	256	46.6%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium	2,023	2,023	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Lonafarnib	12	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Lumasiran	31	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	17	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	14	****	****	****	****	0	NaN	0	NaN	0	NaN
Margetuximab	870	****	****	****	****	****	****	0	NaN	0	NaN



Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of Treatment Episode Durations, Days

				Distribution	or meatiment E	pisouc Burations, Bu	, , ,	
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ansuvimab	0	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-
Berotralstat	392	1	28	56	155	638	114.1	131.6
Copper	549	1	1	1	1	1	1.0	0.0
Gallium	2,023	1	1	1	1	1	1.0	0.0
Lonafarnib	12	22	30	30	30	60	34.3	12.2
Lumasiran	31	1	1	1	15	90	14.4	27.6
Margetuximab	870	1	1	1	1	105	1.5	5.3
Naxitamab	95	1	1	1	1	1	1.0	0.0
Pralsetinib	215	1	30	30	60	478	65.7	82.0
Relugolix	13,734	1	30	58	116	691	86.6	90.6
Remdesivir	7,038	1	1	1	3	10	1.7	1.0
Setmelanotide	****	5	28	45	70	150	57.2	51.4
Tirbanibulin	4,293	1	5	5	15	235	12.1	13.5
Vibegron	81,661	1	30	30	90	594	61.7	65.3

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.



Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

					Numbe	r of Treatment	Episodes by I	Ouration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	****	****	****	****	****	****	****	0	NaN	0	NaN
Male	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
Naxitamab	95	95	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	40	40	42.1%	0	NaN	0	NaN	0	NaN	0	NaN
Male	55	55	57.9%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	215	129	100.0%	53	100.0%	****	****	****	****	0	NaN
Female	123	69	53.5%	34	64.2%	****	****	****	****	0	NaN
Male	92	60	46.5%	19	35.8%	****	****	****	****	0	NaN
Relugolix	13,734	6,064	100.0%	3,936	100.0%	3,422	100.0%	312	100.0%	0	NaN
Female	****	0	0.0%	****	****	0	0.0%	0	0.0%	0	NaN
Male	****	6,064	100.0%	****	****	3,422	100.0%	312	100.0%	0	NaN
Remdesivir	7,038	7,038	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	3,479	3,479	49.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	3,559	3,559	50.6%	0	NaN	0	NaN	0	NaN	0	NaN
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN
Female	****	****	****	****	****	****	****	0	NaN	0	NaN
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Tirbanibulin	4,293	4,183	100.0%	****	****	****	****	0	NaN	0	NaN
Female	2,233	2,166	51.8%	****	****	****	****	0	NaN	0	NaN
Male	2,060	2,017	48.2%	****	****	****	****	0	NaN	0	NaN

cder_mpl1r_wp242 Page 74 of 302



Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

					Numbe	r of Treatment	Episodes by [Ouration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	81,661	45,938	100.0%	23,586	100.0%	11,530	100.0%	607	100.0%	0	NaN
Female	55,525	31,584	68.8%	15,846	67.2%	7,706	66.8%	389	64.1%	0	NaN
Male	26,136	14,354	31.2%	7,740	32.8%	3,824	33.2%	218	35.9%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 75 of 302



Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations, Days Total Number Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 Female 0 Male 0 **Atoltivimab** 0 --Female 0 Male 0 392 Berotralstat 1 28 56 155 638 114.1 131.6 Female 298 4 28 56 140 638 110.6 126.0 Male 94 1 28 56 187 614 125.2 148.2 549 1 1 1 1 1.0 Copper 1 0.0 1 1 1 Female 293 1 1 1.0 0.0 Male 256 1 1 1.0 0.0 1 1 1 1 1 Gallium 2,023 1 1 1 1.0 0.0 **** 1 1 Female 1 1 1 1.0 0.0 **** Male 1 1 1 1 1.0 0.0 1 Lonafarnib 22 30 30 30 60 12 34.3 12.2 **** Female 30 30 45 60 60 45.0 21.2 **** Male 22 30 30 30 60 32.2 10.1 1 1 1 15 90 14.4 Lumasiran 31 27.6 Female 17 1 1 1 15 90 16.8 30.1 Male 1 1 90 11.5 14 1 24.9 870 1 1 1 1 105 1.5 5.3 Margetuximab **** 1 5.3 Female 1 1 1 105 1.5 Male 1 1 1 1 1.0 0.0 1

cder_mpl1r_wp242 Page 76 of 302



Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations, Days **Total Number** Standard of Episodes Minimum Median Maximum Deviation Q1 Q3 Mean **Naxitamab** 95 1 1 1 1 1 1.0 0.0 40 1 1 1 1 1 1.0 0.0 Female Male 55 1 1 1 1 1.0 0.0 1 Pralsetinib 215 1 30 30 60 478 65.7 82.0 Female 123 4 30 30 60 478 92.3 73.1 55.9 Male 92 1 30 30 60 475 65.1 1 Relugolix 13,734 30 58 116 691 86.6 90.6 **** 60 60 60 Female 60 60 60.0 NaN **** Male 1 30 58 116 691 86.6 90.6 1 1 3 Remdesivir 7,038 1 10 1.7 1.0 1 3 Female 3,479 1 1 10 1.8 1.0 Male 2 10 1.7 1.0 3.559 1 1 1 **** 5 Setmelanotide 28 45 70 150 57.2 51.4 **** 5 Female 28 45 70 150 57.2 51.4 Male 0 NaN NaN NaN NaN NaN NaN NaN 5 Tirbanibulin 4,293 1 5 15 235 12.1 13.5 5 5 Female 2,233 1 19 235 12.3 14.3 5 5 Male 2,060 1 14 165 11.7 12.6 1 30 30 90 594 61.7 Vibegron 81,661 65.3 Female 55,525 1 30 30 85 566 60.8 64.4 30 90 594 63.6 67.1 Male 26,136 30

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 77 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Ansuvimab		-	-	-	-	-	-	-	-	-	-	
0-17 years		-	-	-	-	-	-	-	-	-	-	
18-24 years		-	-	-	-	-	-	-	-	-	-	
25-40 years		-	-	-	-	-	-	-	-	-	-	
41-64 years		-	-	-	-	-	-	-	-	-	-	
≥ 65 years		-	-	-	-	-	-	-	-	-	-	
Atoltivimab		-	-	-	-	-	-	-	-	-	-	
0-17 years		-	-	-	-	-	-	-	-	-	-	
18-24 years		-	-	-	-	-	-	-	-	-	-	
25-40 years		-	-	-	-	-	-	-	-	-	-	
41-64 years		-	-	-	-	-	-	-	-	-	-	
≥ 65 years		-	-	-	-	-	-	-	-	-	-	
Berotralstat	392	162	100.0%	95	100.0%	102	100.0%	33	100.0%	0	NaN	
0-17 years	****	****	****	0	0.0%	****	****	****	****	0	NaN	
18-24 years	****	****	****	****	****	****	****	****	****	0	NaN	
25-40 years	66	26	16.0%	14	14.7%	****	****	****	****	0	NaN	
41-64 years	179	75	46.3%	52	54.7%	38	37.3%	14	42.4%	0	NaN	
≥ 65 years	108	43	26.5%	****	****	30	29.4%	****	****	0	NaN	
Copper	549	549	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	

Page 78 of 302



Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

					Numbe	r of Treatment	Episodes by E	Ouration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	302	302	55.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	199	199	36.2%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium	2,023	2,023	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	157	157	7.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,866	1,866	92.2%	0	NaN	0	NaN	0	NaN	0	NaN
Lonafarnib	12	****	****	****	****	0	NaN	0	NaN	0	NaN
0-17 years	12	****	****	****	****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Lumasiran	31	****	****	****	****	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	13	****	****	****	****	0	NaN	0	NaN	0	NaN
41-64 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Margetuximab	870	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN



Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days										
		1-30	Days	31-90	Days	91-365	5 Days	366-73	0 Days	731+	Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	
25-40 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN	
41-64 years	328	328	37.9%	0	0.0%	0	0.0%	0	NaN	0	NaN	
≥ 65 years	523	518	59.9%	****	****	****	****	0	NaN	0	NaN	
Naxitamab	95	95	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	95	95	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Pralsetinib	215	129	100.0%	53	100.0%	****	****	****	****	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
25-40 years	****	0	0.0%	0	0.0%	****	****	0	0.0%	0	NaN	
41-64 years	****	32	24.8%	****	****	****	****	****	****	0	NaN	
≥ 65 years	159	97	75.2%	****	****	****	****	****	****	0	NaN	
Relugolix	13,734	6,064	100.0%	3,936	100.0%	3,422	100.0%	312	100.0%	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
41-64 years	1,185	541	8.9%	316	8.0%	302	8.8%	26	8.3%	0	NaN	
≥ 65 years	12,549	5,523	91.1%	3,620	92.0%	3,120	91.2%	286	91.7%	0	NaN	



Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

					Numbe	r of Treatment	Episodes by I	Duration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remdesivir	7,038	7,038	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	73	73	1.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	71	71	1.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	597	597	8.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	3,016	3,016	42.9%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,281	3,281	46.6%	0	NaN	0	NaN	0	NaN	0	NaN
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	****	****	****	****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Tirbanibulin	4,293	4,183	100.0%	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	****	****	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	2,529	2,481	59.3%	****	****	****	****	0	NaN	0	NaN
≥ 65 years	1,616	1,555	37.2%	****	****	****	****	0	NaN	0	NaN

cder_mpl1r_wp242 Page 81 of 302



Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

					Numbe	r of Treatment	Episodes by [Ouration			
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	81,661	45,938	100.0%	23,586	100.0%	11,530	100.0%	607	100.0%	0	NaN
0-17 years	16	11	0.0%	****	****	****	****	0	0.0%	0	NaN
18-24 years	173	102	0.2%	****	****	****	****	****	****	0	NaN
25-40 years	1,254	730	1.6%	362	1.5%	158	1.4%	****	****	0	NaN
41-64 years	13,240	7,470	16.3%	3,739	15.9%	1,919	16.6%	****	****	0	NaN
≥ 65 years	66,978	37,625	81.9%	19,434	82.4%	9,430	81.8%	489	80.6%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 82 of 302



Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, Days Total Number Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 0-17 years 0 0 18-24 years 25-40 years 0 41-64 years 0 ≥ 65 years 0 **Atoltivimab** 0 0-17 years 0 18-24 years 0 0 25-40 years 41-64 years 0 ≥ 65 years 0 Berotralstat 392 1 28 56 155 638 114.1 131.6 **** 7 0-17 years 28 28 147 554 119.1 178.5 **** 56 18-24 years 15 28 255 535 150.5 164.7 1 95.0 25-40 years 66 28 56 164 392 102.2 41-64 years 179 7 28 56 113 638 106.4 128.8 108 4 28 56 614 123.8 140.9 ≥ 65 years 167 549 1 1 1 1 1 0.0 Copper 1.0

cder_mpl1r_wp242 Page 83 of 302

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1.0

1.0

1.0

1.0

1.0

NaN

0.0

0.0

0.0

0.0

302

199

1

1

1

1

1

1

1

1

1

1

0-17 years

18-24 years

25-40 years

41-64 years

≥ 65 years



Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, Days Total Number Standard of Episodes Minimum Median Q3 Maximum Deviation Q1 Mean Gallium 2.023 1 1 1 1 1 1.0 0.0 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 157 1 1 1 0.0 1 1 1.0 ≥ 65 years 1,866 1 1 1 1 1 1.0 0.0 22 30 30 30 60 Lonafarnib 12 34.3 12.2 0-17 years 12 22 30 30 30 60 34.3 12.2 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN Lumasiran 31 1 1 1 15 90 14.4 27.6 **** 1 1 1 0-17 years 1 30 5.8 11.8 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 13 1 1 1 1 90 11.2 25.2 **** 41-64 years 1 1 1 42 90 22.2 34.6 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 870 1 1 1 1 105 5.3 Margetuximab 1.5 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 19 1 1 1 1 1 1.0 0.0 41-64 years 328 1 1 1 1 1 1.0 0.0 ≥ 65 years 523 1 1 1 105 1.7 6.8 1

cder mpl1r wp242 Page 84 of 302



Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, Days **Total Number** Standard of Episodes Minimum Median Q3 Maximum Deviation Q1 Mean **Naxitamab** 95 1 1 1 1 1 1.0 0.0 0-17 years 95 1 1 1 1 1 1.0 0.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 215 478 Pralsetinib 1 30 30 60 65.7 82.0 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years **** 120 120 120 120 120 120.0 NaN **** 5 41-64 years 30 30 90 475 75.4 93.4 ≥ 65 years 159 30 30 60 478 62.1 77.9 1 1 30 Relugolix 13,734 58 116 691 86.6 90.6 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 1,185 1 30 58 117 614 87.6 95.2 30 58 691 86.5 90.2 ≥ 65 years 12,549 1 116 1 1 1 3 Remdesivir 7,038 10 1.7 1.0 0-17 years 73 1 1 2 3 5 2.0 1.0 71 1 1 1 3 5 1.2 18-24 years 1.8 597 2 25-40 years 1 1 1 6 1.6 1.0 2 5 41-64 years 3,016 1 1 1 1.6 1.0 ≥ 65 years 1 1 1 3 10 1.8 3.281 1.1

cder mpl1r wp242 Page 85 of 302



Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, Days Total Number Standard of Episodes Median Maximum Deviation Minimum Q1 Q3 Mean **** Setmelanotide 5 28 45 70 150 57.2 51.4 **** 5 28 62 70 0-17 years 150 63.0 55.2 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN **** 41-64 years 28 28 28 28 28 28.0 NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 5 Tirbanibulin 4,293 1 5 15 235 12.1 13.5 **** 0-17 years 5 5 5 5 5 5.0 0.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 5 5 25-40 years 5 5 60 10.8 11.0 5 41-64 years 2,529 1 5 5 120 9.9 10.9 1.616 5 5 30 235 16.3 ≥ 65 years 1 15.5 Vibegron 81,661 1 30 30 90 594 61.7 65.3 0-17 years 16 4 30 30 50 120 39.6 28.6 173 2 30 30 78 415 60.5 64.9 18-24 years 25-40 years 1,254 1 30 30 68 456 57.4 59.0 41-64 years 13,240 1 30 30 88 594 62.0 66.1 ≥ 65 years 66,978 30 30 90 566 65.2 1 61.8

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 86 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 202

Number of Patients by First Treatment Episode Duration 1-30 Days 31-90 Days 91-365 Days 366-730 Days 731+ Days Total Percent of Percent of Percent of Percent of Percent of Number Number of **Number of** Total Number of **Number of** Total Number of Total Total Total of Patients **Patients Patients Patients Patients Patients Patients Patients Patients Patients Patients** 0 Ansuvimab Atoltivimab 0 -Berotralstat 191 19.9% 0 0.0% 69 36.1% 38 60 31.4% 24 12.6% 0 Copper 506 506 100.0% 0.0% 0 0.0% 0 0.0% 0 0.0% Gallium 1,879 1,879 100.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% **** **** **** 0 0 0 0.0% Lonafarnib 0.0% 0 0.0% 0.0% **** **** **** **** Lumasiran 0 0.0% 0 0.0% 0 0.0% **** **** **** **** Margetuximab 0 0.0% 0 0.0% 0 0.0% 189 0 0 Naxitamab 14 14 100.0% 0.0% 0 0.0% 0.0% 0 0.0% **** **** **** Pralsetinib 93 58 23 24.7% **** 0 0.0% 62.4% Relugolix 6,670 2,717 40.7% 1,760 26.4% 1,956 29.3% 237 3.6% 0 0.0% Remdesivir 6.834 6.834 100.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0% **** **** **** **** **** **** **** Setmelanotide 0 0.0% 0 0.0% **** **** **** **** Tirbanibulin 3,422 3,341 97.6% 0 0.0% 0 0.0% 41,892 22,393 53.5% 12,200 29.1% 6,797 16.2% 502 1.2% 0 0.0% Vibearon

cder mpl1r wp242 Page 87 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.



Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of First Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Deviation Q1 Maximum Mean Ansuvimab 0 Atoltivimab 0 Berotralstat 191 4 28 73 224 638 145.4 153.4 Copper 506 1 1 1 1 1 1.0 0.0 Gallium 1,879 1 1 1 1 1 1.0 0.0 **** 30 30 30 30 30.0 0.0 Lonafarnib 30 **** Lumasiran 1 1 1 30 56 13.7 19.1 Margetuximab 1 1.9 7.1 189 1 1 1 86 Naxitamab 14 1 1 1 1 1 1.0 0.0 Pralsetinib 93 1 30 30 60 478 61.7 78.5 Relugolix 6,670 1 30 60 135 691 100.1 104.0 Remdesivir 6,834 1 1 3 10 1.7 1.0 1 **** Setmelanotide 28 28 62 70 150 67.6 49.9 5 5 Tirbanibulin 3,422 1 10 120 11.8 12.6 90 68.8 41,892 1 30 30 594 73.3 Vibegron

cder_mpl1r_wp242 Page 88 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.



Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

			Number of Patients by First Treatment Episode Duration											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days			
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients			
Ansuvimab		-	-	-	-	-	-	-	-	-	-			
Female		-	-	-	-	-	-	-	-	-	-			
Male		-	-	-	-	-	-	-	-	-	-			
Atoltivimab		-	-	-	-	-	-	-	-	-	-			
Female		-	-	-	-	-	-	-	-	-	-			
Male		-	-	-	-	-	-	-	-	-	-			
Berotralstat	191	69	100.0%	38	100.0%	60	100.0%	24	100.0%	0	NaN			
Female	142	52	75.4%	****	****	46	76.7%	****	****	0	NaN			
Male	49	17	24.6%	****	****	14	23.3%	****	****	0	NaN			
Copper	506	506	100.0%	0	NaN	0	NaN	0	NaN	0	NaN			
Female	271	271	53.6%	0	NaN	0	NaN	0	NaN	0	NaN			
Male	235	235	46.4%	0	NaN	0	NaN	0	NaN	0	NaN			
Gallium	1,879	1,879	100.0%	0	NaN	0	NaN	0	NaN	0	NaN			
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Lonafarnib	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN			
Lumasiran	****	****	****	****	****	0	NaN	0	NaN	0	NaN			
Female	****	****	****	****	****	0	NaN	0	NaN	0	NaN			
Male	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN			

cder_mpl1r_wp242



Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

		Number of Patients by First Treatment Episode Duration										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Margetuximab	189	****	****	****	****	0	NaN	0	NaN	0	NaN	
Female	188	****	****	****	****	0	NaN	0	NaN	0	NaN	
Male	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN	
Naxitamab	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
Male	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
Pralsetinib	93	58	100.0%	23	100.0%	****	****	****	****	0	NaN	
Female	51	32	55.2%	****	****	****	****	****	****	0	NaN	
Male	42	26	44.8%	****	****	****	****	0	0.0%	0	NaN	
Relugolix	6,670	2,717	100.0%	1,760	100.0%	1,956	100.0%	237	100.0%	0	NaN	
Female	****	0	0.0%	****	****	0	0.0%	0	0.0%	0	NaN	
Male	****	2,717	100.0%	****	****	1,956	100.0%	237	100.0%	0	NaN	
Remdesivir	6,834	6,834	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Female	3,382	3,382	49.5%	0	NaN	0	NaN	0	NaN	0	NaN	
Male	3,452	3,452	50.5%	0	NaN	0	NaN	0	NaN	0	NaN	
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN	
Female	****	****	****	****	****	****	****	0	NaN	0	NaN	
Male	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	
Tirbanibulin	3,422	3,341	100.0%	****	****	****	****	0	NaN	0	NaN	
Female	1,826	1,776	53.2%	****	****	****	****	0	NaN	0	NaN	
Male	1,596	1,565	46.8%	31	39.2%	0	0.0%	0	NaN	0	NaN	

cder_mpl1r_wp242



Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

	_				Number of Pa	tients by First	Treatment Epi	sode Duration	1		
		1-30	1-30 Days		31-90 Days		91-365 Days		0 Days	731+	Days
	Total Number of Patients	Number of Patients	Percent of Total Patients								
Vibegron	41,892	22,393	100.0%	12,200	100.0%	6,797	100.0%	502	100.0%	0	NaN
Female	28,208	15,313	68.4%	8,114	66.5%	4,457	65.6%	324	64.5%	0	NaN
Male	13,684	7,080	31.6%	4,086	33.5%	2,340	34.4%	178	35.5%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 91 of 302



Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of First Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean **Ansuvimab** 0 Female 0 Male 0 **Atoltivimab** 0 Female 0 Male 0 Berotralstat 191 4 28 73 224 638 145.4 153.4 Female 4 28 83 224 142.5 148.9 142 638 Male 49 5 28 57 224 614 153.8 167.2 506 1 1 1 1 1.0 Copper 1 0.0 1 1 Female 271 1 1 1 1.0 0.0 Male 235 1.0 0.0 1 1 1 1 1 1 Gallium 1,879 1 1 1 1 1.0 0.0 **** 1 1 1 Female 1 1 1.0 0.0 **** Male 1 1 1 1 1.0 0.0 1 **** Lonafarnib 30 30 30 30 30.0 0.0 30 **** Female 30 30 30 30 30 30.0 NaN **** Male 30 30 30 30 30 30.0 NaN **** 1 1 1 30 56 13.7 Lumasiran 19.1 Female **** 1 1 1 15 56 14.8 23.8 **** Male 1 30 30 12.6 15.9 1 1 1 1 1 86 1.9 7.1 Margetuximab 189 1 **** 1 1 86 1.9 Female 1 1 7.1

cder_mpl1r_wp242

1

1

1

1.0

NaN

1

1

Male



Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of First Treatment Episode Duration, Days **Total Number** Standard of Patients Median Maximum Deviation Minimum Q1 Q3 Mean **Naxitamab** 14 1 1 1 1 1 1.0 0.0 **** 1 1 1 1 1 1.0 0.0 Female **** Male 1 1 1 1 1.0 0.0 1 Pralsetinib 93 1 30 30 60 478 61.7 78.5 Female 51 4 30 30 60 478 67.3 92.9 Male 42 1 30 30 60 253 55.0 56.8 Relugolix 6,670 1 30 60 135 691 100.1 104.0 **** 60 60 60 60 60.0 Female 60 NaN **** Male 1 30 60 135 691 100.2 104.0 1 1 3 Remdesivir 6,834 1 10 1.7 1.0 1 3 Female 3,382 1 1 10 1.8 1.0 Male 2 10 1.7 3,452 1 1 1 1.0 **** Setmelanotide 28 28 62 70 150 67.6 49.9 **** Female 28 28 62 70 150 67.6 49.9 Male 0 NaN NaN NaN NaN NaN NaN NaN 5 Tirbanibulin 3,422 1 5 10 120 11.8 12.6 5 5 Female 1,826 1 10 120 11.9 13.1 5 5 13 90 Male 1,596 1 11.7 12.1 1 30 30 90 Vibegron 41,892 594 68.8 73.3 Female 28,208 1 30 30 90 564 67.5 72.2 30 30 90 594 71.4 75.3 Male 13,684

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 93 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Patients by First Treatment Episode Duration											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
Ansuvimab		-	-	-	-	-	-	-	-	-	-		
0-17 years		-	-	-	-	-	-	-	-	-	-		
18-24 years		-	-	-	-	-	-	-	-	-	-		
25-40 years		-	-	-	-	-	-	-	-	-	-		
41-64 years		-	-	-	-	-	-	-	-	-	-		
≥ 65 years		-	-	-	-	-	-	-	-	-	-		
Atoltivimab		-	-	-	-	-	-	-	-	-	-		
0-17 years		-	-	-	-	-	-	-	-	-	-		
18-24 years		-	-	-	-	-	-	-	-	-	-		
25-40 years		-	-	-	-	-	-	-	-	-	-		
41-64 years		-	-	-	-	-	-	-	-	-	-		
≥ 65 years		-	-	-	-	-	-	-	-	-	-		
Berotralstat	191	69	100.0%	38	100.0%	60	100.0%	24	100.0%	0	NaN		
0-17 years	****	****	****	0	0.0%	****	****	****	****	0	NaN		
18-24 years	****	****	****	****	****	****	****	****	****	0	NaN		
25-40 years	33	****	****	****	****	****	****	****	****	0	NaN		
41-64 years	82	29	42.0%	****	****	24	40.0%	****	****	0	NaN		
≥ 65 years	55	21	30.4%	****	****	17	28.3%	****	****	0	NaN		
Copper	506	506	100.0%	0	NaN	0	NaN	0	NaN	0	NaN		
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN		

cder_mpl1r_wp242 Page 94 of 302



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Patients by First Treatment Episode Duration										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients							
41-64 years	277	277	54.7%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	183	183	36.2%	0	NaN	0	NaN	0	NaN	0	NaN	
Gallium	1,879	1,879	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
41-64 years	152	152	8.1%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	1,727	1,727	91.9%	0	NaN	0	NaN	0	NaN	0	NaN	
Lonafarnib	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Lumasiran	****	****	****	****	****	0	NaN	0	NaN	0	NaN	
0-17 years	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN	
25-40 years	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN	
41-64 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN	
Margetuximab	189	****	****	****	****	0	NaN	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN	

cder_mpl1r_wp242 Page 95 of 302



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	Number of Patients by First Treatment Episode Duration											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN	
25-40 years	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN	
41-64 years	72	72	38.5%	0	0.0%	0	NaN	0	NaN	0	NaN	
≥ 65 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN	
Naxitamab	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	14	14	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Pralsetinib	93	58	100.0%	23	100.0%	****	****	****	****	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
25-40 years	****	0	0.0%	0	0.0%	****	****	0	0.0%	0	NaN	
41-64 years	****	****	****	****	****	****	****	0	0.0%	0	NaN	
≥ 65 years	74	****	****	****	****	****	****	****	****	0	NaN	
Relugolix	6,670	2,717	100.0%	1,760	100.0%	1,956	100.0%	237	100.0%	0	NaN	
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN	
41-64 years	579	243	8.9%	121	6.9%	193	9.9%	22	9.3%	0	NaN	
≥ 65 years	6,091	2,474	91.1%	1,639	93.1%	1,763	90.1%	215	90.7%	0	NaN	

Page 96 of 302



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	Number of Patients by First Treatment Episode Duration										
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Remdesivir	6,834	6,834	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	72	72	1.1%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	69	69	1.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	577	577	8.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	2,923	2,923	42.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	3,193	3,193	46.7%	0	NaN	0	NaN	0	NaN	0	NaN
Setmelanotide	****	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	****	****	****	****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Tirbanibulin	3,422	3,341	100.0%	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	****	****	****	****	****	0	0.0%	0	NaN	0	NaN
41-64 years	2,098	2,057	61.6%	****	****	****	****	0	NaN	0	NaN
≥ 65 years	1,203	1,164	34.8%	****	****	****	****	0	NaN	0	NaN

cder_mpl1r_wp242 Page 97 of 302



Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Patients by First Treatment Episode Duration									
		1-30	Days	31-90	31-90 Days		5 Days	366-73	0 Days	731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Vibegron	41,892	22,393	100.0%	12,200	100.0%	6,797	100.0%	502	100.0%	0	NaN
0-17 years	****	****	****	****	****	0	0.0%	0	0.0%	0	NaN
18-24 years	****	****	****	****	****	15	0.2%	****	****	0	NaN
25-40 years	642	344	1.5%	195	1.6%	****	****	****	****	0	NaN
41-64 years	6,675	3,503	15.6%	1,923	15.8%	****	****	****	****	0	NaN
≥ 65 years	34,467	18,485	82.5%	10,051	82.4%	5,521	81.2%	410	81.7%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 98 of 302



Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, Days

		Distribution of First Treatment Episode Duration, Days											
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation					
Ansuvimab	0	-	-	-	-	-	-	-					
0-17 years	0	-	-	-	-	-	-	-					
18-24 years	0	-	-	-	-	-	-	-					
25-40 years	0	-	-	-	-	-	-	-					
41-64 years	0	-	-	-	-	-	-	-					
≥ 65 years	0	-	-	-	-	-	-	-					
Atoltivimab	0	-	-	-	-	-	-	-					
0-17 years	0	-	-	-	-	-	-	-					
18-24 years	0	-	-	-	-	-	-	-					
25-40 years	0	-	-	-	-	-	-	-					
41-64 years	0	-	-	-	-	-	-	-					
≥ 65 years	0	-	-	-	-	-	-	-					
Berotralstat	191	4	28	73	224	638	145.4	153.4					
0-17 years	****	28	28	28	147	554	157.0	227.8					
18-24 years	****	28	28	240	391	535	225.3	192.2					
25-40 years	33	4	28	84	224	392	123.8	109.4					
41-64 years	82	7	28	67	196	638	141.9	152.0					
≥ 65 years	55	4	28	56	222	614	139.2	157.2					
Copper	506	1	1	1	1	1	1.0	0.0					
0-17 years	****	1	1	1	1	1	1.0	NaN					
18-24 years	****	1	1	1	1	1	1.0	0.0					
25-40 years	****	1	1	1	1	1	1.0	0.0					
41-64 years	277	1	1	1	1	1	1.0	0.0					
≥ 65 years	183	1	1	1	1	1	1.0	0.0					

cder_mpl1r_wp242



Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean Gallium 1.879 1 1 1 1 1 1.0 0.0 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 152 1 1 1 1 1 1.0 0.0 1,727 0.0 ≥ 65 years 1 1 1 1 1 1.0 **** 30 30 30 30 Lonafarnib 30 30.0 0.0 **** 0-17 years 30 30 30 30 30 30.0 0.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 0 41-64 years NaN NaN NaN NaN NaN NaN NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN **** Lumasiran 1 1 1 30 56 13.7 19.1 **** 1 1 0-17 years 16 30 30 15.5 20.5 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 1 1 8 23 30 11.8 13.8 **** 41-64 years 1 1 1 29 56 14.8 27.5 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 189 1 1 1 1 86 Margetuximab 1.9 7.1 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 1 1 1 1 1 1.0 0.0 41-64 years **** 1 1 1 1 1 1.0 0.0

cder_mpl1r_wp242 Page 100 of 302

1

1

86

2.5

9.3

1

111

≥ 65 years

1



Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean **Naxitamab** 14 1 1 1 1 1 1.0 0.0 0-17 years 14 1 1 1 1 1 0.0 1.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 93 60 Pralsetinib 1 30 30 478 61.7 78.5 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 120 120 120 120 120 120.0 NaN **** 5 41-64 years 30 30 60 210 58.8 54.8 ≥ 65 years 74 30 30 60 478 61.7 83.8 1 1 Relugolix 6,670 30 60 135 691 100.1 104.0 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 579 1 30 60 150 614 108.0 113.2 6,091 30 60 129 99.4 103.0 ≥ 65 years 1 691 1 1 1 3 10 Remdesivir 6,834 1.7 1.0 0-17 years 72 1 1 2 3 5 2.0 1.0 69 1 1 1 3 5 1.9 1.2 18-24 years 2 25-40 years 577 1 1 1 6 1.7 1.0 41-64 years 2,923 1 1 1 2 5 1.6 1.0

cder mpl1r wp242 Page 101 of 302

1

3

1.9

1.1

10

1

3,193

≥ 65 years

1



Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, Days Total Number Standard of Patients Minimum Median Q3 Maximum Deviation Q1 Mean **** Setmelanotide 28 28 62 70 150 67.6 49.9 **** 28 45 66 0-17 years 110 150 77.5 51.6 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN **** 41-64 years 28 28 28 28 28 28.0 NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN 5 5 Tirbanibulin 3,422 1 10 120 11.8 12.6 **** 0-17 years 5 5 5 5 5 5.0 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 5 5 5 5 25-40 years 60 10.5 11.0 5 41-64 years 2,098 1 5 5 120 10.3 11.1 1,203 5 5 105 14.6 14.6 ≥ 65 years 1 30 Vibegron 41,892 1 30 30 90 594 68.8 73.3 **** 0-17 years 15 30 30 52 86 40.5 20.1 **** 2 18-24 years 30 30 90 415 65.3 66.9 25-40 years 642 2 30 30 90 456 64.2 65.5 41-64 years 6,675 1 30 30 90 594 70.4 74.8 ≥ 65 years 30 30 90 549 68.6 73.2 34,467 1

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 102 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

				Number of T	reatment Epi	sodes by Dura	tion (Excludin	g First Treatm	ent Episode)		
		1-30	Days	31-90	Days	91-36	Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes								
Ansuvimab	0	-	-	-	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-	-	-	-
Berotralstat	201	93	46.3%	57	28.4%	****	****	****	****	0	0.0%
Copper	43	43	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gallium	144	144	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Lonafarnib	****	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
Lumasiran	21	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
Margetuximab	681	****	****	****	****	****	****	0	0.0%	0	0.0%
Naxitamab	81	81	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pralsetinib	122	71	58.2%	30	24.6%	****	****	****	****	0	0.0%
Relugolix	7,064	3,347	47.4%	2,176	30.8%	1,466	20.8%	75	1.1%	0	0.0%
Remdesivir	204	204	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Setmelanotide	****	****	****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Tirbanibulin	871	842	96.7%	****	****	****	****	0	0.0%	0	0.0%
Vibegron	39,769	23,545	59.2%	11,386	28.6%	4,733	11.9%	105	0.3%	0	0.0%

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

cder_mpl1r_wp242 Page 103 of 302

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.



Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean 0 Ansuvimab Atoltivimab 0 Berotralstat 201 1 28 48 92 560 84.5 98.4 Copper 43 1 1 1 1 1 1.0 0.0 Gallium 1 1 1 1 1.0 0.0 144 1 **** 22 30 30 30 Lonafarnib 60 35.2 13.3 Lumasiran 21 1 1 1 1 90 14.7 31.2 Margetuximab 4.7 681 1 1 1 105 1.3 1 Naxitamab 81 1 1 1 1 1 1.0 0.0 Pralsetinib 122 4 30 30 60 475 68.8 84.8 Relugolix 7,064 1 30 45 90 558 73.8 73.6 Remdesivir 204 1 1 2 6 1.4 8.0 1 **** 5 5 5 Setmelanotide 5.0 NaN 5 Tirbanibulin 871 1 5 28 235 13.1 16.4 60 566 39,769 1 30 30 54.3 54.6 Vibegron

cder_mpl1r_wp242 Page 104 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented. Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.



Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

				Number of	Treatment Epi	sodes by Dura	tion (Excludin	g First Treatme	ent Episode)		
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes								
Ansuvimab		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Atoltivimab		-	-	-	-	-	-	-	-	-	-
Female		-	-	-	-	-	-	-	-	-	-
Male		-	-	-	-	-	-	-	-	-	-
Berotralstat	201	93	100.0%	57	100.0%	****	****	****	****	0	NaN
Female	156	72	77.4%	45	78.9%	****	****	****	****	0	NaN
Male	45	21	22.6%	12	21.1%	****	****	****	****	0	NaN
Copper	43	43	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	22	22	51.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	21	21	48.8%	0	NaN	0	NaN	0	NaN	0	NaN
Gallium	144	144	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	144	144	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Lonafarnib	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	****	0	0.0%	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Lumasiran	21	****	****	****	****	0	NaN	0	NaN	0	NaN
Female	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Male	****	****	****	****	****	0	NaN	0	NaN	0	NaN
Margetuximab	681	****	****	****	****	****	****	0	NaN	0	NaN

cder_mpl1r_wp242 Page 105 of 302



Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

			Number of Treatment Episodes by Duration (Excluding First Treatment Episode)												
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days				
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes				
Female	****	****	****	****	****	****	****	0	NaN	0	NaN				
Male	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN				
Naxitamab	81	81	100.0%	0	NaN	0	NaN	0	NaN	0	NaN				
Female	34	34	42.0%	0	NaN	0	NaN	0	NaN	0	NaN				
Male	47	47	58.0%	0	NaN	0	NaN	0	NaN	0	NaN				
Pralsetinib	122	71	100.0%	30	100.0%	****	****	****	****	0	NaN				
Female	72	37	52.1%	****	****	****	****	****	****	0	NaN				
Male	50	34	47.9%	****	****	****	****	****	****	0	NaN				
Relugolix	7,064	3,347	100.0%	2,176	100.0%	1,466	100.0%	75	100.0%	0	NaN				
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN				
Male	7,064	3,347	100.0%	2,176	100.0%	1,466	100.0%	75	100.0%	0	NaN				
Remdesivir	204	204	100.0%	0	NaN	0	NaN	0	NaN	0	NaN				
Female	97	97	47.5%	0	NaN	0	NaN	0	NaN	0	NaN				
Male	107	107	52.5%	0	NaN	0	NaN	0	NaN	0	NaN				
Setmelanotide	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN				
Female	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN				
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN				
Tirbanibulin	871	842	100.0%	****	****	****	****	0	NaN	0	NaN				
Female	407	390	46.3%	****	****	****	****	0	NaN	0	NaN				
Male	464	452	53.7%	****	****	****	****	0	NaN	0	NaN				

cder_mpl1r_wp242 Page 106 of 302



Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
		1-30	Days	31-90 Days		91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes							
Vibegron	39,769	23,545	100.0%	11,386	100.0%	4,733	100.0%	105	100.0%	0	NaN	
Female	27,317	16,271	69.1%	7,732	67.9%	3,249	68.6%	65	61.9%	0	NaN	
Male	12,452	7,274	30.9%	3,654	32.1%	1,484	31.4%	40	38.1%	0	NaN	

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 107 of 302



Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 -Female 0 Male 0 **Atoltivimab** 0 _ Female 0 Male 0 201 92 Berotralstat 1 28 48 560 84.5 98.4 Female 156 8 28 47 88 460 81.7 92.1 Male 45 1 28 56 105 560 94.2 118.4 43 1 1 1 1 0.0 Copper 1 1.0 1 1 1 1 Female 22 1 1.0 0.0 Male 21 1.0 0.0 1 1 1 1 1 1 1 1 1 0.0 Gallium 144 1 1.0 0 Female NaN NaN NaN NaN NaN NaN NaN 0.0 Male 144 1 1 1 1.0 1 1 **** 30 30 30 60 13.3 Lonafarnib 22 35.2 **** Female 60 60 60 60 60 60.0 NaN

30

1

1

1

1

1

30

1

15

1

1

1

1

60

90

90

90

105

105

1

32.4

14.7

17.6

10.9

1.3

1.3

1.0

10.7

31.2

33.4

29.7

4.7

4.7

NaN

21

681

22

1

1

1

1

1

1

30

1

1

1

1

1

1

Male

Lumasiran

Female

Female

Male

Margetuximab

Male

cder_mpl1r_wp242 Page 108 of 302



Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Median Q3 Maximum Deviation Q1 Mean **Naxitamab** 81 1 1 1 1 1 1.0 0.0 34 1 1 1 1 0.0 Female 1 1.0 Male 47 1 1 1 1.0 0.0 1 1 Pralsetinib 122 4 30 30 60 475 68.8 84.8 Female 72 4 30 30 68 424 77.2 92.3 50 Male 9 30 30 60 475 56.7 71.9 Relugolix 7,064 1 30 45 90 558 73.8 73.6 0 NaN Female NaN NaN NaN NaN NaN NaN Male 7,064 1 30 45 90 558 73.8 73.6 1 2 6 Remdesivir 204 1 1 1.4 0.8 4 Female 97 1 1 1 1 1.3 0.7 Male 107 2 6 0.9 1 1 1 1.5 **** 5 5 5 5 Setmelanotide 5 5.0 NaN **** 5 5 5 5 5 Female 5.0 NaN Male 0 NaN NaN NaN NaN NaN NaN NaN 5 5 Tirbanibulin 871 1 28 235 13.1 16.4 5 Female 407 2 5 30 235 14.5 18.7 464 5 5 Male 1 14 165 11.9 14.0 30 30 54.6 Vibegron 39,769 1 60 566 54.3 Female 1 30 30 60 566 53.9 54.2 27,317 30 30 55.1 55.5 Male 12,452 508 64

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 109 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Ansuvimab		-	-	-	-	-	-	-	-	-	-	
0-17 years		-	-	-	-	-	-	-	-	-	-	
18-24 years		-	-	-	-	-	-	-	-	-	-	
25-40 years		-	-	-	-	-	-	-	-	-	-	
41-64 years		-	-	-	-	-	-	-	-	-	-	
≥ 65 years		-	-	-	-	-	-	-	-	-	-	
Atoltivimab		-	-	-	-	-	-	-	-	-	-	
0-17 years		-	-	-	-	-	-	-	-	-	-	
18-24 years		-	-	-	-	-	-	-	-	-	-	
25-40 years		-	-	-	-	-	-	-	-	-	-	
41-64 years		-	-	-	-	-	-	-	-	-	-	
≥ 65 years		-	-	-	-	-	-	-	-	-	-	
Berotralstat	201	93	100.0%	57	100.0%	****	****	****	****	0	NaN	
0-17 years	****	****	****	0	0.0%	****	****	0	0.0%	0	NaN	
18-24 years	****	****	****	****	****	****	****	0	0.0%	0	NaN	
25-40 years	33	15	16.1%	****	****	****	****	0	0.0%	0	NaN	
41-64 years	97	****	****	33	57.9%	14	33.3%	****	****	0	NaN	
≥ 65 years	53	****	****	13	22.8%	13	31.0%	****	****	0	NaN	
Copper	43	43	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN	
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN	

cder_mpl1r_wp242 Page 110 of 302



Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30	Days	31-90	Days	91-365	Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	25	25	58.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Gallium	144	144	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Lonafarnib	****	****	****	****	****	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Lumasiran	21	****	****	****	****	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN
41-64 years	****	****	****	****	****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Margetuximab	681	****	****	****	****	****	****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

cder_mpl1r_wp242 Page 111 of 302



Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

				Number of	Treatment Epi	isodes by Dura	tion (Excludin	g First Treatmo	ent Episode)		
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	13	13	1.9%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	256	256	37.8%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	412	****	****	****	****	****	****	0	NaN	0	NaN
Naxitamab	81	81	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	81	81	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Pralsetinib	122	71	100.0%	30	100.0%	****	****	****	****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	37	21	29.6%	****	****	****	****	****	****	0	NaN
≥ 65 years	85	50	70.4%	****	****	****	****	****	****	0	NaN
Relugolix	7,064	3,347	100.0%	2,176	100.0%	1,466	100.0%	****	****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	606	298	8.9%	195	9.0%	109	7.4%	****	****	0	NaN
≥ 65 years	6,458	3,049	91.1%	1,981	91.0%	1,357	92.6%	****	****	0	NaN

cder_mpl1r_wp242 Page 112 of 302



Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

		Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Remdesivir	204	204	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	93	93	45.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	88	88	43.1%	0	NaN	0	NaN	0	NaN	0	NaN
Setmelanotide	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Tirbanibulin	871	842	100.0%	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	26	26	3.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	****	****	****	****	****	0	0.0%	0	NaN	0	NaN
≥ 65 years	413	391	46.4%	****	****	****	****	0	NaN	0	NaN

cder_mpl1r_wp242 Page 113 of 302



Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

				Number of	Treatment Epi	isodes by Dura	tion (Excludin	g First Treatme	nt Episode)		
		1-30	Days	31-90	Days	91-36	5 Days	366-73	0 Days	731+	Days
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Patients	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Vibegron	39,769	23,545	100.0%	11,386	100.0%	4,733	100.0%	105	100.0%	0	NaN
0-17 years	****	****	****	0	0.0%	****	****	0	0.0%	0	NaN
18-24 years	****	****	****	20	0.2%	****	****	****	****	0	NaN
25-40 years	612	386	1.6%	167	1.5%	****	****	****	****	0	NaN
41-64 years	6,565	3,967	16.8%	1,816	15.9%	758	16.0%	****	****	0	NaN
≥ 65 years	32,511	19,140	81.3%	9,383	82.4%	3,909	82.6%	79	75.2%	0	NaN

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 114 of 302



Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 -0-17 years 0 18-24 years 0 25-40 years 0 41-64 years 0 0 ≥ 65 years **Atoltivimab** 0 0-17 years 0 18-24 years 0 25-40 years 0 41-64 years 0 ≥ 65 years 92 Berotralstat 201 1 28 48 560 84.5 98.4 **** 7 0-17 years 18 28 126 224 71.8 102.0 **** 18-24 years 15 28 38 84 196 65.1 56.0 73.5 25-40 years 33 1 28 52 112 252 80.5 41-64 years 97 8 28 42 84 560 76.4 96.2 9 28 56 466 107.8 121.2 ≥ 65 years 53 112 1 43 1 1 1 1 1.0 0.0 Copper 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 1 1 1 1 1 1.0 0.0 41-64 years 25 1 1 1 1 1 1.0 0.0

cder_mpl1r_wp242 Page 115 of 302

1

1

1

1.0

0.0

1

1

≥ 65 years



6.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean Gallium 144 1 1 1 1 1 1.0 0.0 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN **** 41-64 years 1 1 1 1 1 1.0 0.0 **** 0.0 ≥ 65 years 1 1 1 1 1 1.0 **** 22 30 60 Lonafarnib 30 30 35.2 13.3 **** 0-17 years 22 30 30 30 60 13.3 35.2 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN ≥ 65 years NaN NaN NaN NaN NaN NaN NaN Lumasiran 21 1 1 1 1 90 14.7 31.2 **** 1 1 1 1 0-17 years 1 1.0 0.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 25-40 years 1 1 1 1 90 10.9 29.7 **** 41-64 years 1 1 1 56 90 25.9 38.9 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 1 1 1 1 4.7 Margetuximab 681 105 1.3 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 13 1 1 1 1 1 1.0 0.0 41-64 years 256 1 1 1 1 1 1.0 0.0

cder mpl1r wp242 Page 116 of 302

1

1

105

1.5

1

1

412

≥ 65 years



Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Q1 Median Q3 Maximum Deviation Mean **Naxitamab** 81 1 1 1 1 1 1.0 0.0 0-17 years 81 1 1 1 1 1 0.0 1.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN 4 475 84.8 Pralsetinib 122 30 30 60 68.8 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 37 15 30 30 90 475 83.4 107.1 ≥ 65 years 85 4 30 30 60 424 62.4 72.8 1 90 Relugolix 7,064 30 45 558 73.8 73.6 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 606 1 30 37 90 521 68.1 68.6 30 45 90 558 ≥ 65 years 6,458 1 74.3 74.0 204 1 1 1 2 6 0.8 Remdesivir 1.4 **** 0-17 years 1 1 1 1 1 1.0 NaN **** 1 1 2 2 2 1.5 0.7 18-24 years **** 2 3 25-40 years 1 1 1 1.4 0.7 41-64 years 93 1 1 1 1 4 1.3 0.7

cder mpl1r wp242 Page 117 of 302

1

2

6

1.5

0.9

1

88

≥ 65 years

1



Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, Days **Total Number** Standard of Episodes Minimum Median Q3 Maximum Deviation Q1 Mean **** Setmelanotide 5 5 5 5 5 5.0 NaN **** 5 5 5 5 5 0-17 years 5.0 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 0 41-64 years NaN NaN NaN NaN NaN NaN NaN ≥ 65 years 0 NaN NaN NaN NaN NaN NaN NaN 5 28 Tirbanibulin 871 1 5 235 13.1 16.4 **** 0-17 years 5 5 5 5 5 5.0 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN **** 5 25-40 years 5 5 30 30 12.3 11.3 5 41-64 years 431 1 5 5 70 8.4 9.7 413 3 5 5 30 235 18.1 20.4 ≥ 65 years Vibegron 39,769 1 30 30 60 566 54.3 54.6 **** 0-17 years 4 15 30 30 120 38.2 41.5 **** 18-24 years 6 30 30 60 390 54.2 62.1 25-40 years 612 1 30 30 60 452 50.3 50.2 41-64 years 6,565 1 30 30 60 481 53.4 54.5 1 30 30 54.7 ≥ 65 years 32,511 61 566 54.6

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 118 of 302

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of Treatment Episode Gap Durations, Days **Total Number Standard** of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean 0 Ansuvimab Atoltivimab 0 2 Berotralstat 201 1 6 12 202 14.4 30.1 Copper 43 72 124 188 275 434 208.7 101.7 Gallium 144 20 132 188 248 439 195.0 86.9 Lonafarnib 10 5 6 16 20 14.6 8.7 31 5 93 Lumasiran 21 27 50 255 67.1 60.0 Margetuximab 681 1 20 21 15.5 20 351 23.1 Naxitamab 81 1 1 1 23 59 9.6 14.2 3 6 16 Pralsetinib 122 1 192 15.5 25.6 Relugolix 7,064 1 2 4 12 505 12.4 26.3 Remdesivir 204 1 1 2 546 12.8 61.3 1 7 7 7 7 7 Setmelanotide 1 7.0 NaN Tirbanibulin 871 1 21 58 111 470 82.6 85.8 3 7 18 39,769 1 477 17.0 30.0 Vibegron

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 119 of 302



Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Gap Durations, Days

	Distribution of Treatment Episode Gap Durations, Days										
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation			
Ansuvimab	0	-	-	-	-	-	-	-			
Female	0	-	-	-	-	-	-	-			
Male	0	-	-	-	-	-	-	-			
Atoltivimab	0	-	-	-	-	-	-	-			
Female	0	-	-	-	-	-	-	-			
Male	0	-	-	-	-	-	-	-			
Berotralstat	201	1	2	6	12	202	14.4	30.1			
Female	156	1	2	5	8	201	12.0	25.1			
Male	45	1	3	7	15	202	22.6	42.4			
Copper	43	72	124	188	275	434	208.7	101.7			
Female	22	72	118	168	303	434	208.0	114.0			
Male	21	83	145	189	268	415	209.4	89.8			
Gallium	144	20	132	188	248	439	195.0	86.9			
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
Male	144	20	132	188	248	439	195.0	86.9			
Lonafarnib	10	5	6	16	20	31	14.6	8.7			
Female	1	5	5	5	5	5	5.0	NaN			
Male	9	5	8	16	20	31	15.7	8.5			
Lumasiran	21	5	27	50	93	255	67.1	60.0			
Female	12	6	28	44	79	255	71.1	73.5			
Male	9	5	27	88	94	98	61.8	38.9			
Margetuximab	681	1	20	20	21	351	23.1	15.5			
Female	680	1	20	20	21	351	23.1	15.5			
Male	1	20	20	20	20	20	20.0	NaN			

cder_mpl1r_wp242 Page 120 of 302



Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of Treatment Episode Gap Durations, Days **Total Number** Standard of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean **Naxitamab** 81 1 1 1 23 59 9.6 14.2 Female 34 1 1 1 23 59 16.0 10.8 Male 47 1 1 1 23 44 8.8 12.8 Pralsetinib 122 1 3 6 16 192 15.5 25.6 Female 72 1 4 6 21 192 17.4 28.4 50 9 Male 1 3 6 118 12.7 21.0 1 2 4 12 Relugolix 7,064 505 12.4 26.3 Female 0 NaN NaN NaN NaN NaN NaN NaN Male 7,064 1 2 4 12 505 12.4 26.3 1 1 2 Remdesivir 204 1 546 12.8 61.3 1 2 Female 97 1 1 546 12.6 66.7 Male 107 2 430 13.0 56.3 1 1 1 7 7 7 7 7 Setmelanotide 1 7.0 NaN 7 7 7 7 7 Female 1 7.0 NaN Male 0 NaN NaN NaN NaN NaN NaN NaN Tirbanibulin 871 1 21 58 111 470 82.6 85.8 Female 407 1 20 54 101 470 79.3 84.3 464 22 448 85.5 Male 1 62 121 87.2 1 3 7 Vibegron 39,769 18 477 17.0 30.0 Female 27,317 1 3 7 18 477 16.9 30.2 3 7 19 453 29.7 Male 12,452 1 17.3

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 121 of 302



Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, Days

	Total Number							
	of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ansuvimab	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Berotralstat	201	1	2	6	12	202	14.4	30.1
0-17 years	4	1	2	61	161	202	81.3	98.0
18-24 years	14	1	4	8	12	53	13.0	15.2
25-40 years	33	1	1	5	13	110	13.6	24.9
41-64 years	97	1	2	5	14	201	14.9	30.6
≥ 65 years	53	1	2	6	7	139	9.2	19.4
Copper	43	72	124	188	275	434	208.7	101.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	92	92	168	244	244	168.0	107.5
41-64 years	25	83	126	173	220	426	194.6	91.0
≥ 65 years	16	72	136	216	312	434	235.9	116.6

cder_mpl1r_wp242 Page 122 of 302



Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, Days **Total Number** Standard of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean Gallium 144 20 132 188 248 439 195.0 86.9 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 5 36 85 110 251 354 167.2 131.5 ≥ 65 years 439 139 20 132 188 244 196.0 85.4 5 6 Lonafarnib 10 16 20 31 14.6 8.7 0-17 years 5 6 16 20 31 14.6 8.7 10 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 5 Lumasiran 21 27 50 93 255 67.1 60.0 0-17 years 4 27 33 109 217 255 124.8 111.0 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 5 88 25-40 years 9 27 94 98 61.8 38.9 41-64 years 8 6 24 42 68 82 44.3 27.1 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 20 Margetuximab 681 1 20 21 351 23.1 15.5 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 13 19 20 20 27 41 24.1 8.0 41-64 years 256 6 20 20 21 76 22.8 7.7

cder mpl1r wp242 Page 123 of 302

20

20

351

23.3

18.9

20

1

412

≥ 65 years



Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, Days **Total Number** Standard of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean **Naxitamab** 81 1 1 1 23 59 9.6 14.2 0-17 years 81 1 1 1 23 59 9.6 14.2 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 122 3 6 192 Pralsetinib 1 16 15.5 25.6 0-17 years 0 NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 3 5 41-64 years 37 1 21 68 13.8 16.3 ≥ 65 years 85 1 6 13 192 16.2 28.8 4 2 4 Relugolix 7,064 1 12 505 12.4 26.3 0 0-17 years NaN NaN NaN NaN NaN NaN NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 0 25-40 years NaN NaN NaN NaN NaN NaN NaN 41-64 years 606 1 2 5 12 308 15.1 32.6 2 505 ≥ 65 years 6,458 1 4 11 12.2 25.6 1 1 2 61.3 Remdesivir 204 1 546 12.8 0-17 years 1 1 1 1 1 1 1.0 NaN 2 2 2 3 3 3 2.5 0.7 18-24 years 3 99 25-40 years 20 1 1 1 7.5 21.8 2 41-64 years 93 1 1 1 546 11.5 63.3

cder mpl1r wp242 Page 124 of 302

1

1

1

430

15.9

66.4

88

1

≥ 65 years



Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, Days **Total Number** Standard of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean 7 Setmelanotide 1 7 7 7 7 7.0 NaN 0-17 years 1 7 7 7 7 7 7.0 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 470 Tirbanibulin 871 1 21 58 111 82.6 85.8 0-17 years 1 50 50 50 50 50 50.0 NaN 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 26 1 33 64 108 170 75.2 49.0 41-64 years 431 1 25 64 121 470 91.6 91.8 ≥ 65 years 413 1 15 46 101 415 73.7 80.3 3 7 Vibegron 39,769 1 18 477 17.0 30.0 6 3 0-17 years 4 13 34 36 17.0 14.6 9 95 18-24 years 75 1 4 27 17.7 20.1 5 25-40 years 612 1 2 16 243 14.0 26.5 41-64 years 6,565 1 3 6 16 402 15.1 26.8 32,511 3 7 18 477 17.5 30.7 ≥ 65 years 1

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 125 of 302



Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

Distribution of First Treatment Episode Gap Duration, Days **Total Number Standard** of Gaps Minimum Q1 Median Q3 Maximum Deviation Mean 0 Ansuvimab Atoltivimab 0 92 5 Berotralstat 1 2 13 201 16.6 34.1 Copper 42 72 124 189 275 434 210.5 102.2 Gallium 128 20 138 196 265 439 202.9 88.0 Lonafarnib 2 5 5 7 8 8 6.5 2.1 7 5 6 27 98 Lumasiran 82 43.4 36.8 Margetuximab 3 20 20 21 9.9 164 111 22.6 Naxitamab 14 1 1 1 1 59 5.6 15.4 6 Pralsetinib 52 1 4 24 192 19.9 31.6 5 Relugolix 3,269 1 2 14 505 14.4 29.6 Remdesivir 201 1 1 2 546 12.9 61.8 1 7 7 7 7 7 Setmelanotide 1 7.0 NaN Tirbanibulin 571 1 22 64 127 470 90.3 91.2 3 8 22 18,468 1 477 20.4 34.7 Vibegron

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp242 Page 126 of 302



22.7

20.0

9.9

NaN

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of First Treatment Episode Gap Duration, Days **Total Number** Standard of Gaps Minimum Q1 Median Q3 Maximum Deviation Mean **Ansuvimab** 0 Female 0 Male 0 **Atoltivimab** 0 Female 0 Male 0 92 2 5 Berotralstat 1 13 201 16.6 34.1 Female 70 1 1 5 8 14.4 32.4 201 Male 22 1 2 8 20 139 23.7 39.0 42 72 124 189 275 434 210.5 102.2 Copper Female 21 72 118 177 303 434 211.7 115.5 Male 21 83 145 189 268 415 209.4 89.8 88.0 Gallium 128 20 138 196 265 439 202.9 0 Female NaN NaN NaN NaN NaN NaN NaN Male 128 20 138 196 265 439 202.9 88.0 5 2 5 7 8 8 2.1 Lonafarnib 6.5 5 5 5 5 5 Female 1 5.0 NaN Male 8 8 8 8 8 8.0 1 NaN 7 5 6 27 82 98 36.8 Lumasiran 43.4 Female 4 6 17 43 71 82 43.5 33.7 Male 3 5 5 27 98 98 43.3 48.6 164 3 20 20 21 22.6 9.9 Margetuximab 111

cder_mpl1r_wp242 Page 127 of 302

20

20

21

20

111

20

3

20

163

1

Female

Male

20

20



Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Sex

Distribution of First Treatment Episode Gap Duration, Days **Total Number** Standard of Gaps Minimum Q1 Median Q3 Maximum Deviation Mean **Naxitamab** 14 1 1 1 1 59 5.6 15.4 Female 6 1 1 1 3 59 23.5 11.0 Male 8 1 1 1 1 5 1.5 1.4 Pralsetinib 52 1 4 6 24 192 19.9 31.6 Female 31 1 4 13 26 192 24.2 37.7 5 Male 21 1 4 12 72 13.5 18.3 1 2 5 505 Relugolix 3,269 14 14.4 29.6 Female 0 NaN NaN NaN NaN NaN NaN NaN Male 3,269 1 2 5 14 505 14.4 29.6 1 1 2 Remdesivir 201 1 546 12.9 61.8 2 Female 95 1 1 1 546 12.7 67.4 Male 106 2 430 56.6 1 1 1 13.1 7 7 7 7 7 Setmelanotide 1 7.0 NaN 7 7 7 7 7 Female 1 7.0 NaN 0 Male NaN NaN NaN NaN NaN NaN NaN Tirbanibulin 571 1 22 64 127 470 90.3 91.2 Female 268 1 25 61 116 470 89.3 92.3 303 19 422 Male 1 66 134 91.1 90.4 1 3 8 Vibegron 18,468 22 477 20.4 34.7 Female 12,507 1 3 8 22 477 20.3 35.1 1 3 8 23 20.5 Male 5,961 453 33.8

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 128 of 302



Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, Days

	Distribution of First Treatment Episode dap Duration, Days									
	Total Number		_,					Standard		
	of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation		
Ansuvimab	0	-	-	-	-	-	-	-		
0-17 years	0	-	-	-	-	-	-	-		
18-24 years	0	-	-	-	-	-	-	-		
25-40 years	0	-	-	-	-	-	-	-		
41-64 years	0	-	-	-	-	-	-	-		
≥ 65 years	0	-	-	-	-	-	-	_		
Atoltivimab	0	-	-	-	-	-	-	-		
0-17 years	0	-	-	-	-	-	-	-		
18-24 years	0	-	-	-	-	-	-	-		
25-40 years	0	-	-	-	-	-	-	-		
41-64 years	0	-	-	-	-	-	-	-		
≥ 65 years	0	-	-	-	-	-	-	-		
Berotralstat	92	1	2	5	13	201	16.6	34.1		
0-17 years	2	1	1	2	2	2	1.5	0.7		
18-24 years	6	3	4	6	12	40	11.7	14.2		
25-40 years	16	1	1	5	20	110	20.6	33.8		
41-64 years	40	1	2	6	16	201	21.0	41.4		
≥ 65 years	28	1	2	4	8	139	10.1	25.7		
Copper	42	72	124	189	275	434	210.5	102.2		
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN		
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN		
25-40 years	2	92	92	168	244	244	168.0	107.5		
41-64 years	24	83	125	175	232	426	197.2	92.0		
≥ 65 years	16	72	136	216	312	434	235.9	116.6		

cder_mpl1r_wp242 Page 129 of 302



Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, Days

				Distribution of thist	reatment Lpisot	de Gap Duration, Days		
	Total Number		0.4		00		••	Standard
	of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Deviation
Gallium	128	20	138	196	265	439	202.9	88.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	5	36	85	110	251	354	167.2	131.5
≥ 65 years	123	20	142	196	271	439	204.3	86.2
Lonafarnib	2	5	5	7	8	8	6.5	2.1
0-17 years	2	5	5	7	8	8	6.5	2.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Lumasiran	7	5	6	27	82	98	43.4	36.8
0-17 years	1	27	27	27	27	27	27.0	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	3	5	5	27	98	98	43.3	48.6
41-64 years	3	6	6	59	82	82	49.0	39.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Margetuximab	164	3	20	20	21	111	22.6	9.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	5	20	27	27	41	41	31.2	9.4
41-64 years	64	19	20	20	23	76	23.7	9.4
≥ 65 years	95	3	20	20	20	111	21.5	10.1
•								

cder_mpl1r_wp242 Page 130 of 302



Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, Days

	Distribution of First Treatment Episode Gap Duration, Days										
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation			
Naxitamab	14	1	1	1	1	59	5.6	15.4			
0-17 years	14	1	1	1	1	59	5.6	15.4			
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
Pralsetinib	52	1	4	6	24	192	19.9	31.6			
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
41-64 years	14	1	5	15	25	68	19.1	19.3			
≥ 65 years	38	1	4	6	23	192	20.2	35.2			
Relugolix	3,269	1	2	5	14	505	14.4	29.6			
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN			
41-64 years	265	1	3	5	13	253	14.9	26.6			
≥ 65 years	3,004	1	2	5	14	505	14.3	29.9			
Remdesivir	201	1	1	1	2	546	12.9	61.8			
0-17 years	1	1	1	1	1	1	1.0	NaN			
18-24 years	2	2	2	3	3	3	2.5	0.7			
25-40 years	18	1	1	1	2	99	7.4	22.9			
41-64 years	92	1	1	1	2	546	11.6	63.7			
≥ 65 years	88	1	1	1	1	430	15.9	66.4			

cder_mpl1r_wp242 Page 131 of 302



Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, Days **Total Number** Standard of Gaps Minimum Median Q3 Maximum Deviation Q1 Mean Setmelanotide 1 7 7 7 7 7 7.0 NaN 0-17 years 1 7 7 7 7 7 7.0 NaN 0 18-24 years NaN NaN NaN NaN NaN NaN NaN 25-40 years 0 NaN NaN NaN NaN NaN NaN NaN 41-64 years 0 NaN NaN NaN NaN NaN NaN NaN 0 ≥ 65 years NaN NaN NaN NaN NaN NaN NaN 90.3 91.2 Tirbanibulin 571 1 22 64 127 470 0-17 years 1 50 50 50 50 50.0 NaN 50 18-24 years 0 NaN NaN NaN NaN NaN NaN NaN 25-40 years 17 1 49 65 111 169 79.2 49.3 41-64 years 315 1 25 66 142 470 99.1 97.5 ≥ 65 years 238 15 54 116 403 79.5 83.7 1 3 8 Vibegron 18,468 1 22 477 20.4 34.7 3 3 3 0-17 years 15 34 34 17.3 15.6 5 9 18-24 years 41 1 25 95 19.0 21.8 7 25-40 years 274 1 3 19 231 16.2 26.3 41-64 years 3,062 1 3 7 19 402 17.3 30.5 15,088 1 3 23 477 21.1 35.6 ≥ 65 years

Data presented by a dash, asterisk, or period represent missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder mpl1r wp242 Page 132 of 302



Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

							Censorin	g Reason					
		End of E Epis	xposure ode ²	Occurence of Request- Defined Censoring Criteria ³		Evidence	of Death⁴	Disenro	llment ⁵	End of Data Partner Data ⁶		End of Query Period	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ansuvimab	0	-	-	-	-	-	-	-	-	-	-	-	-
Atoltivimab	0	-	-	-	-	-	-	-	-	-	-	-	-
Berotralstat	392	382	97.4%	0	0.0%	****	****	****	****	101	25.8%	0	0.0%
Copper	549	549	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Gallium	2,023	****	****	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
Lonafarnib	12	****	****	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
Lumasiran	31	31	100.0%	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
Margetuximab	870	****	****	0	0.0%	****	****	****	****	****	****	0	0.0%
Naxitamab	95	95	100.0%	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
Pralsetinib	215	****	****	0	0.0%	****	****	40	18.6%	38	17.7%	0	0.0%
Relugolix	13,734	13,465	98.0%	0	0.0%	130	0.9%	3,790	27.6%	3,743	27.3%	0	0.0%
Remdesivir	7,038	****	****	0	0.0%	****	****	27	0.4%	30	0.4%	0	0.0%
Setmelanotide	****	****	****	0	0.0%	0	0.0%	****	****	****	****	0	0.0%
Tirbanibulin	4,293	****	****	0	0.0%	****	****	132	3.1%	120	2.8%	0	0.0%
Vibegron	81,661	79,718	97.6%	0	0.0%	414	0.5%	22,210	27.2%	22,657	27.7%	0	0.0%

cder_mpl1r_wp242 Page 133 of 302



Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022¹

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

Data presented by a dash, asterisk, or period represent missing information. This table may not use all data representations.

cder mpl1r wp242 Page 134 of 302

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁴Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷Represents episodes censored due to user-specified study end date.

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.



Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

	Ansuv	vimab	Atolti	vimab	Berotralstat		
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	
Members meeting enrollment and demographic requirements							
Enrolled at any point during the query period	164,447,346	N/A	164,447,346	N/A	164,447,346	N/A	
Had required coverage type (medical and/or drug coverage)	102,772,646	61,674,700	102,772,646	61,674,700	102,772,646	61,674,700	
Enrolled during specified age range	102,771,753	893	102,771,753	893	102,771,753	893	
Had requestable medical charts	102,771,753	0	102,771,753	0	102,771,753	0	
Met demographic requirements (sex, race, and Hispanic origin)	102,072,104	699,649	102,072,104	699,649	102,072,104	699,649	
Members with a valid index event							
Had any cohort-defining claim during the query period	0	102,072,104	0	102,072,104	232	102,071,872	
Claim recorded during specified age range	0	0	0	0	232	0	
Episode defining index claim recorded during the query period	0	0	0	0	232	0	
Met exposure incidence criteria	0	0	0	0	232	0	
Members with required pre-index history							
Had sufficient pre-index continuous enrollment	0	0	0	0	191	41	
Met inclusion and exclusion criteria	0	0	0	0	191	0	
Members with required post-index follow-up							
Had sufficient post-index continuous enrollment	0	0	0	0	191	0	
Final cohort							
Number of members	0	N/A	0	N/A	191	N/A	
Number of episodes	0	N/A	0	N/A	191	N/A	

cder_mpl1r_wp242 Page 135 of 302



Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

	Copper		Gallium		Lonafarnib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	164,447,346	N/A	164,447,346	N/A	164,447,346	N/A
Had required coverage type (medical and/or drug coverage)	102,772,646	61,674,700	102,772,646	61,674,700	102,772,646	61,674,700
Enrolled during specified age range	102,771,753	893	102,771,753	893	102,771,753	893
Had requestable medical charts	102,771,753	0	102,771,753	0	102,771,753	0
Met demographic requirements (sex, race, and Hispanic origin)	102,072,104	699,649	102,072,104	699,649	102,072,104	699,649
Members with a valid index event						
Had any cohort-defining claim during the query period	565	102,071,539	1,987	102,070,117	****	102,072,102
Claim recorded during specified age range	565	0	1,987	0	****	0
Episode defining index claim recorded during the query period	565	0	1,987	0	****	0
Met exposure incidence criteria	565	0	1,987	0	****	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	506	59	1,879	108	****	0
Met inclusion and exclusion criteria	506	0	1,879	0	****	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	506	0	1,879	0	****	0
Final cohort						
Number of members	506	N/A	1,879	N/A	****	N/A
Number of episodes	506	N/A	1,879	N/A	****	N/A

cder_mpl1r_wp242 Page 136 of 302



Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

	Lumasiran		Margetuximab		Naxitamab	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	164,447,346	N/A	164,447,346	N/A	164,447,346	N/A
Had required coverage type (medical and/or drug coverage)	102,772,646	61,674,700	102,772,646	61,674,700	102,772,646	61,674,700
Enrolled during specified age range	102,771,753	893	102,771,753	893	102,771,753	893
Had requestable medical charts	102,771,753	0	102,771,753	0	102,771,753	0
Met demographic requirements (sex, race, and Hispanic origin)	102,072,104	699,649	102,072,104	699,649	102,072,104	699,649
Members with a valid index event						
Had any cohort-defining claim during the query period	12	102,072,092	208	102,071,896	16	102,072,088
Claim recorded during specified age range	12	0	208	0	16	0
Episode defining index claim recorded during the query period	12	0	208	0	16	0
Met exposure incidence criteria	12	0	208	0	16	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	****	****	189	19	14	****
Met inclusion and exclusion criteria	****	0	189	0	14	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	****	0	189	0	14	0
Final cohort						
Number of members	****	N/A	189	N/A	14	N/A
Number of episodes	****	N/A	189	N/A	14	N/A

cder_mpl1r_wp242 Page 137 of 302



Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

	Pralsetinib		Relugolix		Remo	lesivir
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	164,447,346	N/A	164,447,346	N/A	164,447,346	N/A
Had required coverage type (medical and/or drug coverage)	102,772,646	61,674,700	102,772,646	61,674,700	102,772,646	61,674,700
Enrolled during specified age range	102,771,753	893	102,771,753	893	102,771,753	893
Had requestable medical charts	102,771,753	0	102,771,753	0	102,771,753	0
Met demographic requirements (sex, race, and Hispanic origin)	102,072,104	699,649	102,072,104	699,649	102,072,104	699,649
Members with a valid index event						
Had any cohort-defining claim during the query period	105	102,071,999	7,198	102,064,906	7,859	102,064,245
Claim recorded during specified age range	105	0	7,198	0	7,859	0
Episode defining index claim recorded during the query period	105	0	7,198	0	7,859	0
Met exposure incidence criteria	105	0	7,198	0	7,859	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	93	12	6,670	528	6,834	1,025
Met inclusion and exclusion criteria	93	0	6,670	0	6,834	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	93	0	6,670	0	6,834	0
Final cohort						
Number of members	93	N/A	6,670	N/A	6,834	N/A
Number of episodes	93	N/A	6,670	N/A	6,834	N/A

cder_mpl1r_wp242 Page 138 of 302



Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

	Setmelanotide		Tirbanibulin		Vibegron	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	164,447,346	N/A	164,447,346	N/A	164,447,346	N/A
Had required coverage type (medical and/or drug coverage)	102,772,646	61,674,700	102,772,646	61,674,700	102,772,646	61,674,700
Enrolled during specified age range	102,771,753	893	102,771,753	893	102,771,753	893
Had requestable medical charts	102,771,753	0	102,771,753	0	102,771,753	0
Met demographic requirements (sex, race, and Hispanic origin)	102,072,104	699,649	102,072,104	699,649	102,072,104	699,649
Members with a valid index event						
Had any cohort-defining claim during the query period	****	102,072,099	3,732	102,068,372	44,856	102,027,248
Claim recorded during specified age range	****	0	3,732	0	44,855	****
Episode defining index claim recorded during the query period	****	0	3,732	0	44,855	0
Met exposure incidence criteria	****	0	3,732	0	44,855	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	****	0	3,422	310	41,892	2,963
Met inclusion and exclusion criteria	****	0	3,422	0	41,892	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	****	0	3,422	0	41,892	0
Final cohort						
Number of members	****	N/A	3,422	N/A	41,892	N/A
Number of episodes	****	N/A	3,422	N/A	41,892	N/A

^{*****}Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

cder_mpl1r_wp242 Page 139 of 302



Figure 1a. Patient Entry into Study by Month for Ansuvimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on December 21, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 140 of 302



Figure 1b. Patient Entry into Study by Month for Atoltivimab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on October 14, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 141 of 302



Figure 1c. Patient Entry into Study by Month for Berotralstat in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022


*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on December 3, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 142 of 302



Figure 1d. Patient Entry into Study by Month for Copper in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022




The FDA approval date for this drug was on September 3, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 143 of 302



Figure 1e. Patient Entry into Study by Month for Gallium in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022



The FDA approval date for this drug was on December 1, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 144 of 302



Figure 1f. Patient Entry into Study by Month for Lonafarnib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on November 20, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 145 of 302



Figure 1g. Patient Entry into Study by Month for Lumasiran in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on November 23, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 146 of 302



Figure 1h. Patient Entry into Study by Month for Margetuximab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on December 16, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 147 of 302



Figure 1i. Patient Entry into Study by Month for Naxitamab in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022

*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on November 25, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 148 of 302



Figure 1j. Patient Entry into Study by Month for Pralsetinib in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022


*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on September 4, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 149 of 302



Figure 1k. Patient Entry into Study by Month for Relugolix in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022




The FDA approval date for this drug was on December 18, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 150 of 302



Figure 1l. Patient Entry into Study by Month for Remdesivir in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022



The FDA approval date for this drug was on October 22, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 151 of 302



Figure 1m. Patient Entry into Study by Month for Setmelanotide in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022


*****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

The FDA approval date for this drug was on November 25, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 152 of 302



Figure 1n. Patient Entry into Study by Month for Tirbanibulin in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022




The FDA approval date for this drug was on December 14, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 153 of 302



Figure 1o. Patient Entry into Study by Month for Vibegron in the Sentinel Distributed Database (SDD) from January 1, 2020 to December 31, 2022



The FDA approval date for this drug was on December 23, 2020 as listed on the FDA website: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020

cder_mpl1r_wp242 Page 154 of 302



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 11, 2023)

Masked DP ID ¹	DP Start Date	DP End Date ¹
DP01	01/01/2000	08/31/2022
DP02	01/01/2000	07/31/2022
DP03	01/01/2000	05/31/2022
DP04	01/01/2004	11/30/2022
DP05	01/01/2007	09/30/2022
DP06	01/01/2008	08/31/2022
DP07	01/01/2005	07/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	10/31/2022
DP10	01/01/2010	09/30/2022
DP11	01/01/2008	12/31/2022
DP12	01/01/2006	10/31/2022

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

cder_mpl1r_wp242 Page 155 of 302



Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
	vibegron
vibegron	Gemtesa
	ansuvimab
ansuvimab-zykl	Ebanga
	relugolix
relugolix	orgovyx
	margetuximab
margetuximab-cmkb	Margenza
	tirbanibulin
tirbanibulin	Klisyri
	berotralstat
berotralstat hydrochloride	Orladeyo
	gallium
gallium Ga-68 gozetotide	Gallium Ga 68 PSMA-11
gallium Ga-68 gozetotide	Gallium Ga 68 PSMA-12
	naxitamab
naxitamab-gqgk	Danyelza
	setmelanotide
setmelanotide acetate	Imcivree
	lumasiran
lumasiran sodium	Oxlumo
	lonafarnib
lonafarnib	Zokinvy
	remdesivir
remdesivir	Veklury
remdesivir	remdesivir
	atoltivimab
atoltivimab, maftivimab, and odesivimab-ebgn	Inmazeb
	pralsetinib
pralsetinib	Gavreto
	copper
copper Cu-64 dotatate	Detectnet

cder_mpl1r_wp242 Page 156 of 302



Appendix C. List of Procedure Codes for Medical Products Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
margetuximab			
J9353	Injection, margetuximab-cmkb, 5 mg	Procedure	HCPCS
gallium			
A9593	Gallium Ga-68 PSMA-11, diagnostic, (UCSF), 1 mCi	Procedure	HCPCS
A9594	Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 mCi	Procedure	HCPCS
naxitamab			
J9348	Injection, naxitamab-gqgk, 1 mg	Procedure	HCPCS
lumasiran			
C9074	Injection, lumasiran, 0.5 mg	Procedure	HCPCS
J0224	Injection, lumasiran, 0.5 mg	Procedure	HCPCS
remdesivir			
J0248	Injection, remdesivir, 1 mg	Procedure	HCPCS
copper			
A9592	Copper Cu-64, dotatate, diagnostic, 1 mCi	Procedure	HCPCS

cder_mpl1r_wp242 Page 157 of 302



Code	Description	Code Category	Code Type
Acquired	Hypothyroidism		
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	lodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol A	buse		
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 158 of 302



Code	Description	Code Category	Code Type
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
91.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
03.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
03.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
03.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
03.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
03.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
03.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
05.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
05.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
05.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
57.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
25.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
35.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
35.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
71.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
71.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
71.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
71.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
50.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
4.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
4.61	Alcohol rehabilitation	Procedure	ICD-9-CM
4.62	Alcohol detoxification	Procedure	ICD-9-CM
4.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
1.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
1.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
1.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
30.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 159 of 302



Code	Description	Code Category	Code Type
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 160 of 302



Code	Description	Code Category	Code Type
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 161 of 302



Code	Description	Code Category	Code Type
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
(70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
/ 65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
/ 79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 162 of 302



Code	Description	Code Category	Code Type
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Acute My	ocardial Infraction		
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 163 of 302



Code	Description	Code Category	Code Type
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
121.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
121.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
121.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
121.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
121.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
121.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
121.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
121.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
121.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
121.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
122.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
122.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
122.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
123.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 164 of 302



Code	Description	Code Category	Code Type
23.7	Postinfarction angina	Diagnosis	ICD-10-CM
23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
81.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
82.44	Beta thalassemia	Diagnosis	ICD-9-CM
82.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
82.46	Thalassemia minor	Diagnosis	ICD-9-CM
82.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
82.49	Other thalassemia	Diagnosis	ICD-9-CM
82.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
82.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 165 of 302



Code	Description	Code Category	Code Type
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
82.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
82.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
83.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
83.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
83.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
83.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
83.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
83.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
84.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
84.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
84.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
84.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
84.19	Other pancytopenia	Diagnosis	ICD-9-CM
84.2	Myelophthisis	Diagnosis	ICD-9-CM
84.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
84.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
84.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
85.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
85.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
85.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
85.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
85.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
85.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
85.8	Other specified anemias	Diagnosis	ICD-9-CM
85.9	Unspecified anemia	Diagnosis	ICD-9-CM
94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 166 of 302



D46.0 Refractory anemia with brut ring sideroblasts, so stated Diagnosis ICD-10-CM D46.1 Refractory anemia with ring sideroblasts, unspecified Diagnosis ICD-10-CM D46.21 Refractory anemia with excess of blasts, unspecified Diagnosis ICD-10-CM D46.22 Refractory anemia with excess of blasts 2 Diagnosis ICD-10-CM D46.24 Refractory anemia with excess of blasts 2 Diagnosis ICD-10-CM D46.4 Refractory cytopenie with sulfillineage dysplasia Diagnosis ICD-10-CM D46.9 Myelodysplastic syndrome, unspecified Diagnosis ICD-10-CM D46.8 Refractory cytopenia with multilineage dysplasia and ring sideroblasts Diagnosis ICD-10-CM D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality Diagnosis ICD-10-CM D46.C Other myelodysplastic syndromes Diagnosis	Code	Description	Code Category	Code Type
D46.2.0Refractory anemia with excess of blasts, unspecifiedDiagnosisICD-10-CMD46.2.1Refractory anemia with excess of blasts 1DiagnosisICD-10-CMD46.2.2Refractory anemia with excess of blasts 2DiagnosisICD-10-CMD46.4Refractory anemia, unspecifiedDiagnosisICD-10-CMD46.9Myelodysplastic syndrome, unspecifiedDiagnosisICD-10-CMD46.8Refractory cytopenia with multilineage dysplasiaDiagnosisICD-10-CMD46.8Refractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.6Myelodysplastic syndrome with isolated del[5q] chromosomal abnormalityDiagnosisICD-10-CMD46.7Other myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.2Iron deficiency anemiaDiagnosisICD-10-CMD50.3Other iron deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD	D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.21Refractory anemia with excess of blasts 1DiagnosisICD-10-CMD46.22Refractory anemia with excess of blasts 2DiagnosisICD-10-CMD46.4Refractory anemia, unspecifiedDiagnosisICD-10-CMD46.9Myelodysplastic syndrome, unspecifiedDiagnosisICD-10-CMD46.8Refractory cytopenia with multilineage dysplasiaDiagnosisICD-10-CMD46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.COther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.2Other iron deficiency anemiaDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CM<	D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.22Refractory anemia with excess of blasts 2DiagnosisICD-10-CMD46.4Refractory anemia, unspecifiedDiagnosisICD-10-CMD46.9Myelodysplastic syndrome, unspecifiedDiagnosisICD-10-CMD46.ARefractory cytopenia with multilineage dysplasiaDiagnosisICD-10-CMD46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.COther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaICD-10-CMDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2 </td <td>D46.20</td> <td>Refractory anemia with excess of blasts, unspecified</td> <td>Diagnosis</td> <td>ICD-10-CM</td>	D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.4Refractory anemia, unspecifiedDiagnosisICD-10-CMD46.9Myelodysplastic syndrome, unspecifiedDiagnosisICD-10-CMD46.ARefractory cytopenia with multilineage dysplasiaICD-10-CMD46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD52.0<	D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.9Myelodysplastic syndrome, unspecifiedDiagnosisICD-10-CMD46.ARefractory cytopenia with multilineage dysplasiaDiagnosisICD-10-CMD46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD52.1DiagnosisICD-10-CMDiagnosisICD-10-CMD52.2DiagnosisICD-10-CMDiagnosisICD-10-CMD52.1Other folate deficiency anemiaDi	D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.ARefractory cytopenia with multilineage dysplasiaDiagnosisICD-10-CMD46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiaDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.1Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.2Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.3Other folate deficiency anemiaDiagnosisICD-10-CMD52.4Other folate deficiency anemiaDiagnosisICD-10-CMD53.1Protein deficiency anemia	D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.BRefractory cytopenia with multilineage dysplasia and ring sideroblastsDiagnosisICD-10-CMD46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.2Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.3Other folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.1Protein deficiency anemiaDiagnosisICD-10-CMD53.2Corbutic anemiaDiagnosis	D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormalityDiagnosisICD-10-CMD46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Torucin deficiency anemiaDiagnosisICD-10-CMD52.3Other folate deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-C	D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.ZOther myelodysplastic syndromesDiagnosisICD-10-CMD47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Other folate deficiency anemiaDiagnosisICD-10-CMD52.3Folate deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemiaDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.3Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.8Other	D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D47.4OsteomyelofibrosisDiagnosisICD-10-CMD50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.3Other vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.3Other folate deficiency anemiaDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.3Other specified nutritional anemiasICD-10-CM	D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D50.0Iron deficiency anemia secondary to blood loss (chronic)DiagnosisICD-10-CMD50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Other folate deficiency anemiaDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classified <td< td=""><td>D46.Z</td><td>Other myelodysplastic syndromes</td><td>Diagnosis</td><td>ICD-10-CM</td></td<>	D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D50.1Sideropenic dysphagiaDiagnosisICD-10-CMD50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietarry vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiaDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasICD-10-CM	D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.8Other iron deficiency anemiasDiagnosisICD-10-CMD50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.3Other specified nutritional anemiasICD-10-CM	D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.9Iron deficiency anemia, unspecifiedDiagnosisICD-10-CMD51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.2Other folate deficiency anemiasDiagnosisICD-10-CMD52.3Other folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.3Other specified nutritional anemiasDiagnosisICD-10-CM	D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D51.0Vitamin B12 deficiency anemia due to intrinsic factor deficiencyDiagnosisICD-10-CMD51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D51.1Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuriaDiagnosisICD-10-CMD51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.2Transcobalamin II deficiencyDiagnosisICD-10-CMD51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.3Other dietary vitamin B12 deficiency anemiaDiagnosisICD-10-CMD51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.8Other vitamin B12 deficiency anemiasDiagnosisICD-10-CMD51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.9Vitamin B12 deficiency anemia, unspecifiedDiagnosisICD-10-CMD52.0Dietary folate deficiency anemiaDiagnosisICD-10-CMD52.1Drug-induced folate deficiency anemiaDiagnosisICD-10-CMD52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D52.0 Dietary folate deficiency anemia Diagnosis ICD-10-CM D52.1 Drug-induced folate deficiency anemia Diagnosis ICD-10-CM D52.8 Other folate deficiency anemias Diagnosis ICD-10-CM D52.9 Folate deficiency anemia, unspecified Diagnosis ICD-10-CM D53.0 Protein deficiency anemia Diagnosis ICD-10-CM D53.1 Other megaloblastic anemias, not elsewhere classified Diagnosis ICD-10-CM D53.2 Scorbutic anemia Diagnosis ICD-10-CM D53.8 Other specified nutritional anemias	D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D52.1 Drug-induced folate deficiency anemia Diagnosis ICD-10-CM D52.8 Other folate deficiency anemias Diagnosis ICD-10-CM D52.9 Folate deficiency anemia, unspecified Diagnosis ICD-10-CM D53.0 Protein deficiency anemia Diagnosis ICD-10-CM D53.1 Other megaloblastic anemias, not elsewhere classified Diagnosis ICD-10-CM D53.2 Scorbutic anemia Diagnosis ICD-10-CM D53.8 Other specified nutritional anemias	D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.8Other folate deficiency anemiasDiagnosisICD-10-CMD52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.9Folate deficiency anemia, unspecifiedDiagnosisICD-10-CMD53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D53.0Protein deficiency anemiaDiagnosisICD-10-CMD53.1Other megaloblastic anemias, not elsewhere classifiedDiagnosisICD-10-CMD53.2Scorbutic anemiaDiagnosisICD-10-CMD53.8Other specified nutritional anemiasDiagnosisICD-10-CM	D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D53.1 Other megaloblastic anemias, not elsewhere classified Diagnosis ICD-10-CM D53.2 Scorbutic anemia Diagnosis ICD-10-CM D53.8 Other specified nutritional anemias ICD-10-CM	D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.2 Scorbutic anemia Diagnosis ICD-10-CM D53.8 Other specified nutritional anemias Diagnosis ICD-10-CM	D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.8 Other specified nutritional anemias Diagnosis ICD-10-CM	D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
	D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.9 Nutritional anemia, unspecified Diagnosis ICD-10-CM	D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
	D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 167 of 302



Code	Description	Code Category	Code Type
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 168 of 302



Code	Description	Code Category	Code Type
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 169 of 302



Code	Description	Code Category	Code Type
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 170 of 302



Code	Description	Code Category	Code Type
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
064.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
193.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
193.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
193.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
193.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
193.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
193.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
193.82	Cough variant asthma	Diagnosis	ICD-9-CM
193.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
193.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
193.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 171 of 302



Code	Description	Code Category	Code Type
45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
45.991	Cough variant asthma	Diagnosis	ICD-10-CM
145.998	Other asthma	Diagnosis	ICD-10-CM
82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Atrial Fibri	illation		
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 172 of 302



Code	Description	Code Category	Code Type
Benign Pro	ostatic Hyperplasia		
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Breast Can	ncer		
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 173 of 302



Code	Description	Code Category	Code Type
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 174 of 302



Code	Description	Code Category	Code Type
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 175 of 302



Code	Description	Code Category	Code Type
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arr	est		
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kid	ney Disease		
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 176 of 302



Code	Description	Code Category	Code Type
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 177 of 302



Code	Description	Code Category	Code Type
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
83.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
83.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
83.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
83.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
83.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases	Diagnosis	ICD-9-CM
	classified elsewhere		
83.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
83.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
84.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
84.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
84.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
84.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
84.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
85.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
85.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
85.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
85.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
85.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
85.6	End stage renal disease	Diagnosis	ICD-9-CM
85.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 178 of 302



Code	Description	Code Category	Code Type
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
418.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
352.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
030.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 179 of 302



Code	Description	Code Category	Code Type
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
112.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
112.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney	Diagnosis	ICD-10-CM
	disease		
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 180 of 302



Code	Description	Code Category	Code Type
113.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
(76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
И10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
И10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
/l10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
110.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
/10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
/l10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
/l10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
/l10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
/10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
/10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
110.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
/ 10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
110.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
110.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
110.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
110.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
110.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
110.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
/l10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
И10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 181 of 302



Code	Description	Code Category	Code Type
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
√32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
∕/35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
0.00	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
100.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
100.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
100.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
100.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
100.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
100.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
100.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
8.001	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
100.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
100.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
101.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
101.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
101.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
101.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
101.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
101.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
I01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
102.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 182 of 302



Code	Description	Code Category	Code Type
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 183 of 302



Code	Description	Code Category	Code Type
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 184 of 302



Code	Description	Code Category	Code Type
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
80 <i>V</i>	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
113.39	Other hydronephrosis	Diagnosis	ICD-10-CM
114.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
114.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
114.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
114.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
115.0	Balkan nephropathy	Diagnosis	ICD-10-CM
15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
18.6	End stage renal disease	Diagnosis	ICD-10-CM
118.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
l19	Unspecified kidney failure	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 185 of 302



Code	Description	Code Category	Code Type
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal	Cancer		
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 186 of 302



Code	Description	Code Category	Code Type
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 187 of 302



Code	Description	Code Category	Code Type
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obs	structive Pulmonary Disease		
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 188 of 302



Code	Description	Code Category	Code Type
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary A	Angioplasty Bypass		
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depressio	n		
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 189 of 302



Code	Description	Code Category	Code Type
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 190 of 302



Code	Description	Code Category	Code Type
31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
32.8	Other depressive episodes	Diagnosis	ICD-10-CM
32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
32.A	Depression, unspecified	Diagnosis	ICD-10-CM
33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 191 of 302



Code	Description	Code Category	Code Type
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
49.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
49.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
49.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
49.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
49.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
49.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
49.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
49.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
50.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 192 of 302



Code	Description	Code Category	Code Type
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
50.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
50.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
50.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
50.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
57.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
62.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
62.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 193 of 302



Code	Description	Code Category	Code Type
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 194 of 302



Code	Description	Code Category	Code Type
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
	eye		
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left	Diagnosis	ICD-10-CM
	еуе		
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,	Diagnosis	ICD-10-CM
	bilateral		
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	right eye		
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	left eye		
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
	bilateral		
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
	eye		
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right	•	ICD-10-CM
	eye		
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left	Diagnosis	ICD-10-CM
30.0.0	eye	. 6	

cder_mpl1r_wp242 Page 195 of 302



Code	Description	Code Category	Code Type
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 196 of 302



Code	Description	Code Category	Code Type
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal	Diagnosis	ICD-10-CM
	detachment and rhegmatogenous retinal detachment, unspecified eye		
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 197 of 302



Code	Description	Code Category	Code Type
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma	Diagnosis	ICD-10-CM
	(NKHHC)		
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 198 of 302



Code	Description	Code Category	Code Type
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 199 of 302



Code	Description	Code Category	Code Type
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 200 of 302



Code	Description	Code Category	Code Type
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment	Diagnosis	ICD-10-CM
	and rhegmatogenous retinal detachment, bilateral		
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment	Diagnosis	ICD-10-CM
	and rhegmatogenous retinal detachment, unspecified eye		
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 201 of 302



Code	Description	Code Category	Code Type
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 202 of 302



Code	Description	Code Category	Code Type
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right	Diagnosis	ICD-10-CM
	eye		
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula,	Diagnosis	ICD-10-CM
	bilateral		
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula,	Diagnosis	ICD-10-CM
	unspecified eye		

cder_mpl1r_wp242 Page 203 of 302



Code	Description	Code Category	Code Type
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,	Diagnosis	ICD-10-CM
	right eye		
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left	Diagnosis	ICD-10-CM
	еуе		
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,	Diagnosis	ICD-10-CM
	bilateral		
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,	Diagnosis	ICD-10-CM
	unspecified eye		
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, right eye		
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, left eye		
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, bilateral		
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, unspecified eye		
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 204 of 302



Code	Description	Code Category	Code Type
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
11.311		=	ICD-1

cder_mpl1r_wp242 Page 205 of 302



Code	Description	Code Category	Code Type
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 206 of 302



Code	Description	Code Category	Code Type
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 207 of 302



Code	Description	Code Category	Code Type
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 208 of 302



Code	Description	Code Category	Code Type
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 209 of 302



Code	Description	Code Category	Code Type
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified	Diagnosis	ICD-10-CM
	eye		
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 210 of 302



Code	Description	Code Category	Code Type
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the	Diagnosis	ICD-10-CM
	macula, bilateral		
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the	Diagnosis	ICD-10-CM
	macula, unspecified eye		
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, right eye		
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, left eye		
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, bilateral		
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and	Diagnosis	ICD-10-CM
	rhegmatogenous retinal detachment, unspecified eye		
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 211 of 302



Code	Description	Code Category	Code Type
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abus	e		
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
	Onisid truss demandance enisedia	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CIVI

cder_mpl1r_wp242 Page 212 of 302



Code	Description	Code Category	Code Type
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
804.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 213 of 302



Code	Description	Code Category	Code Type
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
05.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
805.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
05.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
805.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
05.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
05.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
05.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
05.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
05.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
805.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
805.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
805.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 214 of 302



Code	Description	Code Category	Code Type
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
548.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
548.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
48.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
48.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
548.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
555.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
55.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
55.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
55.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
60.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
60.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
60.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
79.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
4.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
4.64	Drug rehabilitation	Procedure	ICD-9-CM
4.65	Drug detoxification	Procedure	ICD-9-CM
4.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
4.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
4.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
4.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
65.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
65.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
65.01	Poisoning by heroin	Diagnosis	ICD-9-CM
65.02	Poisoning by methadone	Diagnosis	ICD-9-CM
65.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 215 of 302



Code	Description	Code Category	Code Type
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 216 of 302



Code	Description	Code Category	Code Type
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 217 of 302



Code	Description	Code Category	Code Type
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 218 of 302



Code	Description	Code Category	Code Type
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 219 of 302



Code	Description	Code Category	Code Type
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
-13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242



Code	Description	Code Category	Code Type
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 221 of 302



Code	Description	Code Category	Code Type
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 222 of 302



Code	Description	Code Category	Code Type
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 223 of 302



Code	Description	Code Category	Code Type
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 224 of 302



Code	Description	Code Category	Code Type
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 225 of 302



Code	Description	Code Category	Code Type
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 226 of 302



Code	Description	Code Category	Code Type
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 227 of 302



Code	Description	Code Category	Code Type
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 228 of 302



Code	Description	Code Category	Code Type
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 229 of 302



Code	Description	Code Category	Code Type
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 230 of 302



Code	Description	Code Category	Code Type
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometria	l Cancer		
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 231 of 302



Code	Description	Code Category	Code Type
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
65.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
65.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
865.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
65.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
65.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
65.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
65.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
65.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
65.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
65.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
65.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
65.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
65.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
65.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
65.83	Aqueous misdirection	Diagnosis	ICD-9-CM
65.89	Other specified glaucoma	Diagnosis	ICD-9-CM
865.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 232 of 302



Code	Description	Code Category	Code Type
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 233 of 302



Code	Description	Code Category	Code Type
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 234 of 302



Code	Description	Code Category	Code Type
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
140.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
140.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
140.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
140.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
140.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
140.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
140.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
140.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
140.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
140.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
140.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
140.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
140.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
140.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
140.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
140.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 235 of 302



Code	Description	Code Category	Code Type
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 236 of 302



Code	Description	Code Category	Code Type
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 237 of 302



Code	Description	Code Category	Code Type
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 238 of 302



Code	Description	Code Category	Code Type
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 239 of 302



Code	Description	Code Category	Code Type
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 240 of 302



Code	Description	Code Category	Code Type
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failu	re		
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 241 of 302



Code	Description	Code Category	Code Type
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
109.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
111.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
113.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
113.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
142.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
142.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
142.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
142.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
142.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
143	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
150.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
150.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 242 of 302



Code	Description	Code Category	Code Type
50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
50.811	Acute right heart failure	Diagnosis	ICD-10-CM
50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
150.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
50.83	High output heart failure	Diagnosis	ICD-10-CM
50.84	End stage heart failure	Diagnosis	ICD-10-CM
50.89	Other heart failure	Diagnosis	ICD-10-CM
50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
- Typerlipid	emia		
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 243 of 302



Code	Description	Code Category	Code Type
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertens	ion		
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 244 of 302



Code	Description	Code Category	Code Type
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
105.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
105.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
137.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
135.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
113.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 245 of 302



Code	Description	Code Category	Code Type
113.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
113.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
113.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
115.0	Renovascular hypertension	Diagnosis	ICD-10-CM
115.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
115.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
115.8	Other secondary hypertension	Diagnosis	ICD-10-CM
115.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
167.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
schemic F	Heart Disease		
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
110.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
10.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
10.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
110.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
10.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
10.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
10.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
10.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
10.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
10.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
10.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
10.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
110.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
110.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 246 of 302



Code	Description	Code Category	Code Type
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
110.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
110.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
110.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
10.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
110.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
110.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
10.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
10.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
11.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
11.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
11.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
11.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
12	Old myocardial infarction	Diagnosis	ICD-9-CM
13.0	Angina decubitus	Diagnosis	ICD-9-CM
13.1	Prinzmetal angina	Diagnosis	ICD-9-CM
13.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
14.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
14.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
14.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
14.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
14.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
14.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
14.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
14.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
14.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
14.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 247 of 302



Code	Description	Code Category	Code Type
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
120.0	Unstable angina	Diagnosis	ICD-10-CM
120.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
120.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
120.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
121.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
121.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
121.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
121.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
121.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
121.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
121.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
121.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
121.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
122.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
122.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
122.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
122.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
122.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
123.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
123.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 248 of 302



Code	Description	Code Category	Code Type
123.7	Postinfarction angina	Diagnosis	ICD-10-CM
123.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
124.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
124.1	Dressler's syndrome	Diagnosis	ICD-10-CM
124.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
124.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
125.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
125.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
125.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.2	Old myocardial infarction	Diagnosis	ICD-10-CM
125.3	Aneurysm of heart	Diagnosis	ICD-10-CM
25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
125.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
125.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
125.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
125.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
125.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 249 of 302



Code	Description	Code Category	Code Type
125.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
125.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
125.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
ung Cance	er		
62.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
62.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
62.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
62.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
62.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
62.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 250 of 302



Code	Description	Code Category	Code Type
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 251 of 302



Code	Description	Code Category	Code Type
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 252 of 302



Code	Description	Code Category	Code Type
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 253 of 302



Code	Description	Code Category	Code Type
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
OD1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 254 of 302



Code	Description	Code Category	Code Type
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
OD1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
OD1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
OD1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
ODB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
ODB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
ODB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
ODB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
ODB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
ODBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

cder_mpl1r_wp242 Page 255 of 302



Code	Description	Code Category	Code Type
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
OTRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 256 of 302



Code	Description	Code Category	Code Type
099.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
099.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
099.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
099.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
099.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 257 of 302



Code	Description	Code Category	Code Type
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporos	is and the second s		
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 258 of 302



Code	Description	Code Category	Code Type
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 259 of 302



Code	Description	Code Category	Code Type
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CN
√80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CN
AX88.08N	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
AXA8.08N	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CN
√81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CN
∕/81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
∕/81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CN
Overweight			
66.3	Overweight	Diagnosis	ICD-10-CN
68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CN
68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CN
68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CN
rostate Car	ncer		
85	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
33.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CN
07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CN
10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CN
heumatoid	Arthritis		
14.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
14.1	Felty's syndrome	Diagnosis	ICD-9-CM
14.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
14.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
14.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
14.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
14.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
15.00	Generalized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
15.04	Generalized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM

cder_mpl1r_wp242



Code	Description	Code Category	Code Type
715.09	Generalized osteoarthrosis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
715.13	Primary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthrosis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthrosis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthrosis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthrosis, shoulder region	Diagnosis	ICD-9-CM
15.22	Secondary localized osteoarthrosis, upper arm	Diagnosis	ICD-9-CM
15.23	Secondary localized osteoarthrosis, forearm	Diagnosis	ICD-9-CM
15.24	Secondary localized osteoarthrosis, involving hand	Diagnosis	ICD-9-CM
15.25	Secondary localized osteoarthrosis, pelvic region and thigh	Diagnosis	ICD-9-CM
15.26	Secondary localized osteoarthrosis, lower leg	Diagnosis	ICD-9-CM
15.27	Secondary localized osteoarthrosis, ankle and foot	Diagnosis	ICD-9-CM
15.28	Secondary localized osteoarthrosis, other specified site	Diagnosis	ICD-9-CM
15.30	Localized osteoarthrosis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
15.31	Localized osteoarthrosis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
15.32	Localized osteoarthrosis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
15.33	Localized osteoarthrosis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
15.34	Localized osteoarthrosis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
15.35	Localized osteoarthrosis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
15.36	Localized osteoarthrosis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
15.37	Localized osteoarthrosis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
15.38	Localized osteoarthrosis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
15.80	Osteoarthrosis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthrosis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
15.90	Osteoarthrosis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 261 of 302



Code	Description	Code Category	Code Type
715.91	Osteoarthrosis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthrosis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthrosis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthrosis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthrosis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthrosis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthrosis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthrosis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 262 of 302



Code	Description	Code Category	Code Type
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 263 of 302



Code	Description	Code Category	Code Type
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 264 of 302



Code	Description	Code Category	Code Type
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 265 of 302



Code	Description	Code Category	Code Type
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 266 of 302



Code	Description	Code Category	Code Type
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 267 of 302



Code	Description	Code Category	Code Type
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 268 of 302



Code	Description	Code Category	Code Type
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 269 of 302



Code	Description	Code Category	Code Type
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 270 of 302



Code	Description	Code Category	Code Type
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 271 of 302



Code	Description	Code Category	Code Type
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 272 of 302



Code	Description	Code Category	Code Type
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 273 of 302



Code	Description	Code Category	Code Type
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 274 of 302



Code	Description	Code Category	Code Type
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 275 of 302



Code	Description	Code Category	Code Type
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 276 of 302



Code	Description	Code Category	Code Type
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 277 of 302



Code	Description	Code Category	Code Type
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 278 of 302



Code	Description	Code Category	Code Type
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 279 of 302



Code	Description	Code Category	Code Type
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 280 of 302



Code	Description	Code Category	Code Type
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 281 of 302



Code	Description	Code Category	Code Type
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if	Procedure	CPT-2
	identified as a tobacco user (PV, CAD)		

cder_mpl1r_wp242 Page 282 of 302



Code	Description	Code Category	Code Type
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
099.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 283 of 302



Code	Description	Code Category	Code Type
099.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
099.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
099.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
099.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Is	chemic Attack		
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM

cder_mpl1r_wp242 Page 284 of 302



Code	Description	Code Category	Code Type
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	latrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
645.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
645.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
645.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
345.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
645.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
646.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
346.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
646.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
646.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
646.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
646.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
646.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
646.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
50.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
50.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
50.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
50.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
50.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
50.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 285 of 302



Code	Description	Code Category	Code Type
160.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
50.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
50.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
50.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
50.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
50.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
50.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
50.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
8.03	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
50.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
51.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
1.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
1.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
1.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
1.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
1.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
1.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
1.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
1.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
2.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
2.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
2.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
2.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
3.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
3.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
3.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
3.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
53.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
53.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 286 of 302



Code	Description	Code Category	Code Type
163.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
163.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
53.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
3.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
53.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
53.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
53.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
53.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
53.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
53.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
53.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
53.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
53.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
53.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
53.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
53.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
53.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
53.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
53.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 287 of 302



Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
163.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
163.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
163.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
163.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
163.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
163.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
163.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
163.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
163.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
163.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
163.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
163.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
163.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
163.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
163.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
163.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
163.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
163.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
163.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
163.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
163.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 288 of 302



Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
163.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
53.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
53.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
53.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
3.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
3.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
3.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
53.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
53.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
53.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
53.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
53.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
53.8	Other cerebral infarction	Diagnosis	ICD-10-CM
53.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
3.89	Other cerebral infarction	Diagnosis	ICD-10-CM
53.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
6.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
6.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
56.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 289 of 302



Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
166.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
166.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
166.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
166.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
166.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
166.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
166.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
166.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
167.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
167.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
167.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
197.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
197.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
197.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
197.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

cder_mpl1r_wp242 Page 290 of 302



Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCI/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4
Nicotine Polacrilex	Stop Smoking Aid

cder_mpl1r_wp242 Page 291 of 302



Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

cder_mpl1r_wp242 Page 292 of 302



Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2020 (part 3) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Query period: 01/01/2020 - 12/31/2022

Coverage requirement: Medical and Drug Coverage

Pre-index enrollment requirement: 183

Post-index requirement: 0 days

Enrollment gap: 45 days

Age groups: 0-17, 18-24, 25-40, 41-64, 65+ years

Stratifications: Age group, Sex

Restrictions: Male and Female

Distribution of index-defining codes: No

Envelope macro: Reclassify encounters during inpatient stay as inpatient

Freeze data: No

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Copper Cu 64 Dotatate Injection	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	Pralsetinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Atoltivimad, maftivimab, and odesivimab-ebgn	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

cder_mpl1r_wp242 Page 293 of 302



Appendix F. Specifications Defining Parameters for this Request Exposure Incident **Exclude evidence of days** supply if exposure exposure Treatment Treatment Principal Create Index Exposure/ washout washout includes episode episode diagnosis **Baseline** Censor treatment Scenario **Event Cohort definition** Table? episode at evidence of: period dispensings extension Care setting position gap Disenrollment; Death; First valid index date during Any care Any 0 N/A 4 Remdesivir 0 days 0 days Yes Data Partner End Date; setting query period Query End Date Disenrollment; Death; First valid index date during Any care Any 0 Data Partner End Date; 5 Lonafarnib N/A 0 days 0 days Yes setting query period Query End Date Disenrollment; Death; First valid index date during Any care Any Lumasiran 0 N/A 0 days 0 days Yes Data Partner End Date; 6 query period setting Query End Date Disenrollment; Death; First valid index date during Any care Any 7 Setmelanotide 0 N/A 0 days 0 days Yes Data Partner End Date; query period setting Query End Date Disenrollment; Death; First valid index date during Any care Any 8 Naxitamab-gqgk 0 N/A 0 days 0 days Yes Data Partner End Date; query period setting Query End Date Disenrollment; Death; Gallium 68 PSMA-First valid index date during Any care Any 9 0 N/A Data Partner End Date; 0 days 0 days Yes 11 query period setting Query End Date

cder_mpl1r_wp242 Page 294 of 302



				Exposure						
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
10	Berotralstat	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Tirbanibulin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Margetuximab (anti-HER2 mAB)	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

cder_mpl1r_wp242 Page 295 of 302



Appendix F. Specifications Defining Parameters for this Request

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
13	Relugolix	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	Ansuvimab-zykl	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Vibegron	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

N/A: Not Applicable

cder_mpl1r_wp242 Page 296 of 302



Appendix G. Parameters Used to Define Baseline Characteristics for this Request

Baseline Characteristic	Care Setting/Principal Diagnosis ¹	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Baseline Characteristic Includes Dispensing	Number of Instances the Baseline Characteristic Should be Found in Evaluation Period	Forced Supply to Attach to Dispensing
Chronic Conditions Data Warehous	e					
Acute Myocardial Infarction	IPP, IPS	-183	-1	N/A	1	N/A
Alzheimer's Disease and related conditions	Any	-183	-1	N/A	1	N/A
Atrial Fibrillation	IPP, IPS or	-183	-1	N/A	1	N/A
Atriai Fibriliation	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Diabetes	IP*, IS*	-183	-1	N/A	1	N/A
Diabetes	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Heart Failure	IP*, AV*, ED*	-183	-1	N/A	1	N/A
Hyperlipidemia	IP*, IS*	-183	-1	N/A	1	N/A
пуренириченна	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Hyportonsian	IP*, IS*	-183	-1	N/A	1	N/A
Hypertension	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Depression	Any	-183	-1	N/A	1	N/A
Ischemic Heart Disease	Any	-183	-1	N/A	1	N/A

cder_mpl1r_wp242 Page 297 of 302



Appendix G. Parameters Used to Define Baseline Characteristics for this Request

Baseline Characteristic	Care Setting/Principal Diagnosis ¹	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Baseline Characteristic Includes Dispensing	Number of Instances the Baseline Characteristic Should be Found in Evaluation Period	Forced Supply to Attach to Dispensing
Rheumatoid Arthritis/Osteoarthritis	Any	-183	-1	N/A	2	N/A
Straka/TIA	IP*	-183	-1	N/A	1	N/A
Stroke/TIA	AV*, ED*, OA*	-183	-1	N/A	2	N/A
Breast Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
Breast Cancer	AV*, ED* OA*	-183	-1	N/A	2	N/A
Colorectal Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
Colorectal Cancer	AV*, ED* OA*	-183	-1	N/A	2	N/A
Prostate Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
riostate Calicei	AV*, ED* OA*	-183	-1	N/A	2	N/A
Lung Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
Lung Cancer	AV*, ED* OA*	-183	-1	N/A	2	N/A

cder_mpl1r_wp242 Page 298 of 302



Appendix G. Parameters Used to Define Baseline Characteristics for this Request

Baseline Characteristic	Care Setting/Principal Diagnosis ¹	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Baseline Characteristic Includes Dispensing	Number of Instances the Baseline Characteristic Should be Found in Evaluation Period	Forced Supply to Attach to Dispensing
Endometrial Cancer	IP*, IS* or	-183	-1	N/A	1	N/A
Endometrial Cancer	AV*, ED* OA*	-183	-1	N/A	2	N/A
	IP*, IS*, or	-183	-1	N/A	1	N/A
Acquired Hypothyroidism	AV*, ED* OA*	-183	-1	N/A	2	N/A
Anemia	Any	-183	-1	N/A	1	N/A
Asthma	IP*, IS*, or	-183	-1	N/A	1	N/A
Astnma	AV*, ED* OA*	-183	-1	N/A	2	N/A
Davis Davistis II. va suslasis	IP*, IS*, or	-183	-1	N/A	1	N/A
Benign Prostatic Hyperplasia	AV*, ED* OA*	-183	-1	N/A	2	N/A
Characia Kida ya Disasa	IP*, IS*, or	-183	-1	N/A	1	N/A
Chronic Kidney Disease	AV*, ED* OA*	-183	-1	N/A	2	N/A
CODD and Draw his starie	IP*, IS*, or	-183	-1	N/A	1	N/A
COPD and Bronchiectasis	AV*, ED* OA*	-183	-1	N/A	2	N/A
Glaucoma	AV*, ED*, OA*	-183	-1	N/A	2	N/A

cder_mpl1r_wp242



Appendix G. Parameters Used to Define Baseline Characteristics for this Request

Baseline Characteristic	Care Setting/Principal Diagnosis ¹	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Baseline Characteristic Includes Dispensing	Number of Instances the Baseline Characteristic Should be Found in Evaluation Period	Forced Supply to Attach to Dispensing
Osteoporosis	IP*, IS*, or	-183	-1	N/A	1	N/A
	AV*, ED* OA*	-183	-1	N/A	2	N/A
Other						
Obesity	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	Any	-183	-1	N/A	1	N/A
Smoking	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A

cder_mpl1r_wp242



Appendix G. Parameters Used to Define Baseline Characteristics for this Request

Baseline Characteristic	Care Setting/Principal Diagnosis ¹	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Baseline Characteristic Includes Dispensing	Number of Instances the Baseline Characteristic Should be Found in Evaluation Period	Forced Supply to Attach to Dispensing
Alcohol Abuse or Dependence	Any	-183	-1	N/A	1	N/A
Drug Abuse or Dependence	Any	-183	-1	N/A	1	N/A
History of Cardiac Arrest	Any	-183	-1	N/A	1	N/A
History of Coronary Angioplasty or Bypass	Any	-183	-1	N/A	1	N/A

^{*}These codes must be within 365 days of the index date, not each other as in version 1.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.


Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not Applicable

cder_mpl1r_wp242 Page 301 of 302

¹Caresetting/ Principal Diagnosis





¹ Includes all valid exposure episodes during the query period; only the first valid episode's incidence is assessed using the washout period.

Window I: Age, sex, year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

cder_mpl1r_wp242 Page 302 of 302

²15 scenarios defined based on initiation of NMEs approved in 2020 Part 3 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME

³Baseline characteristics:

⁴Censoring: earliest of death, disenrollment, data partner data end date, query end date